<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">JBPC</journal-id><journal-title-group><journal-title>Journal of Biophysical Chemistry</journal-title></journal-title-group><issn pub-type="epub">2153-036X</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.4236/jbpc.2023.141001</article-id><article-id pub-id-type="publisher-id">JBPC-123424</article-id><article-categories><subj-group subj-group-type="heading"><subject>Articles</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>Chemistry&amp;Materials Science</subject></subj-group></article-categories><title-group><article-title>
 
 
  Design of N-11-Azaartemisinins Potentially Active against &lt;i&gt;Plasmodium falciparum&lt;/i&gt; by Combined Molecular Electrostatic Potential, Ligand-Receptor Interaction and Models Built with Supervised Machine Learning Methods
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Jeferson</surname><given-names>Stiver Oliveira de Castro</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>José</surname><given-names>Ciríaco Pinheiro</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="corresp" rid="cor1"><sup>*</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Sílvia</surname><given-names>Simone dos Santos de Morais</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Heriberto</surname><given-names>Rodrigues Bitencourt</given-names></name><xref ref-type="aff" rid="aff4"><sup>4</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Antonio</surname><given-names>Florêncio de Figueiredo</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Marcos</surname><given-names>Antonio Barros dos Santos</given-names></name><xref ref-type="aff" rid="aff5"><sup>5</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Fábio</surname><given-names>dos Santos Gil</given-names></name><xref ref-type="aff" rid="aff6"><sup>6</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Ana</surname><given-names>Cecília Barbosa Pinheiro</given-names></name><xref ref-type="aff" rid="aff7"><sup>7</sup></xref></contrib></contrib-group><aff id="aff6"><addr-line>Laboratório de Química Teórica e Computacional, Universidade Federal do Pará, Belém, PA, Brasil</addr-line></aff><aff id="aff1"><addr-line>Instituto de Educa&amp;amp;#231;&amp;amp;#227;o, Ci&amp;amp;#234;ncia e Tecnologia do Pará, Castanhal, PA, Brasil</addr-line></aff><aff id="aff7"><addr-line>Funda&amp;amp;#231;&amp;amp;#227;o Santa Casa de Misericórdia do Pará, Belém, PA, Brasil</addr-line></aff><aff id="aff3"><addr-line>Universidade do Estado do Amapá, Macapá, AP, Brasil</addr-line></aff><aff id="aff2"><addr-line>Instituto Amaz&amp;amp;#244;nia dos Saberes, S&amp;amp;#227;o Luís, MA, Brasil</addr-line></aff><aff id="aff5"><addr-line>Universidade do Estado do Pará, Belém, PA, Brasil</addr-line></aff><aff id="aff4"><addr-line>Laboratório de Síntese, Universidade Federal do Pará, Belém, PA, Brasil</addr-line></aff><pub-date pub-type="epub"><day>28</day><month>02</month><year>2023</year></pub-date><volume>14</volume><issue>01</issue><fpage>1</fpage><lpage>29</lpage><history><date date-type="received"><day>7,</day>	<month>January</month>	<year>2023</year></date><date date-type="rev-recd"><day>25,</day>	<month>February</month>	<year>2023</year>	</date><date date-type="accepted"><day>28,</day>	<month>February</month>	<year>2023</year></date></history><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  N-11-azaartemisinins potentially active against 
  <em>Plasmodium falciparum</em> are designed by combining molecular electrostatic potential (MEP), ligand-receptor interaction, and models built with supervised machine learning methods (PCA, HCA, KNN, SIMCA, and SDA). The optimization of molecular structures was performed using the B3LYP/6-31G* approach. MEP maps and ligand-receptor interactions were used to investigate key structural features required for biological activities and likely interactions between N-11-azaartemisinins and heme, respectively. The supervised machine learning methods allowed the separation of the investigated compounds into two classes: 
  <em>cha</em> and 
  <em>cla</em>, with the properties 
  <em>ε</em>
  <sub>LUMO+1</sub> (one level above lowest unoccupied molecular orbital energy), 
  <em>d</em>(C
  <sub>6</sub>-C
  <sub>5</sub>) (distance between C
  <sub>6</sub> and C
  <sub>5</sub> atoms in ligands), and TSA (total surface area) responsible for the classification. The insights extracted from the investigation developed and the chemical intuition enabled the design of sixteen new N-11-azaartemisinins (prediction set), moreover, models built with supervised machine learning methods were applied to this prediction set. The result of this application showed twelve new promising N-11-azaartemisinins for synthesis and biological evaluation.
 
</p></abstract><kwd-group><kwd>Antimalarial Design</kwd><kwd> MEP</kwd><kwd> Ligand-Receptor Interaction</kwd><kwd> Supervised Machine Learning Methods</kwd><kwd> Models Built with Supervised Machine Learning Methods</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>1. Introduction</title><p>Malaria is a potentially fatal disease caused by parasites of the genus Plasmodium, transmitted by the female Anopheles mosquito. According to the literature [<xref ref-type="bibr" rid="scirp.123424-ref1">1</xref>] , in 2020, ~241 million cases of malaria occurred worldwide, compared to ~227 million cases in 2019 and ~231 million cases in 2017; with the majority of these cases being concentrated in the African continent (~228 million or 95% of the incidence), followed by Southeast Asia (~2% of the total cases).</p><p>There are four species of human malaria (P. falciparum, P. vivax, P. malariae, and P. ovale). P. falciparum is the most prevalent parasite in the African region with ~82.2% of cases, in Southeast Asia (~10.0%), in the Eastern Mediterranean (~4.9%), and in the Western Pacific (~1.8%). P. vivax predominates in the Americas region, representing ~1% of malaria cases. P. falciparum is the most dangerous, as it multiplies very quickly in the bloodstream and causes severe anemia [<xref ref-type="bibr" rid="scirp.123424-ref1">1</xref>] . In addition, it has cytoadherence properties that favor the sequestration of the parasite in the brain microcirculation, which can lead to death in some patients. In several regions of the world, it has shown resistance to antimalarial compounds of different chemical classes [<xref ref-type="bibr" rid="scirp.123424-ref2">2</xref>] .</p><p>In Brazil, the Legal Amazon, which comprises the states of Amazonas, Acre, Maranh&#227;o, Par&#225;, Rond&#244;nia, and Roraima, accounts for ~99.7% of all malaria cases. In order to understand the reasons for this high rate of the disease in the Amazon region, it is necessary to understand how this area was occupied in the past [<xref ref-type="bibr" rid="scirp.123424-ref3">3</xref>] .</p><p>Although Malaria is a very old infectious disease, it still generates serious public health problems, threatening its control. One of the main reasons for this fact refers to the ability of the Plasmodium protozoan to resist the discovered drugs [<xref ref-type="bibr" rid="scirp.123424-ref2">2</xref>] .</p><p>Currently, efforts continue in the search for medicines [<xref ref-type="bibr" rid="scirp.123424-ref4">4</xref>] - [<xref ref-type="bibr" rid="scirp.123424-ref17">17</xref>] that can help to overcome this disease that still afflicts a large part of humanity. The World Health Organization (WHO) recommends 14 drugs for curative treatment of malaria and 4 drugs for prophylactic treatment, with these treatments being formulated as a single drug or as combinations, and artemisinin and its derivatives appear as essential in these formulations [<xref ref-type="bibr" rid="scirp.123424-ref7">7</xref>] .</p><p>Among the synthesized artemisinin derivatives that show efficiency in combating P. falciparum, 11-azaartemisinin and its N-substituted derivatives have attracted the attention of researchers [<xref ref-type="bibr" rid="scirp.123424-ref18">18</xref>] [<xref ref-type="bibr" rid="scirp.123424-ref19">19</xref>] [<xref ref-type="bibr" rid="scirp.123424-ref20">20</xref>] [<xref ref-type="bibr" rid="scirp.123424-ref21">21</xref>] , as they have great advantages over artemisinin and other derivatives already used in the treatment of malaria (dihydroartemisinin, artesunate and arthemeter). These derivatives are easily prepared from artemisinin (<xref ref-type="fig" rid="fig1">Figure 1</xref>(a)) and some of them show remarkable thermal stability [<xref ref-type="bibr" rid="scirp.123424-ref18">18</xref>] . Its starting compound (11-azaartemisinin) contains a six-membered lactam unit other than the lactone unit of artemisinin (<xref ref-type="fig" rid="fig1">Figure 1</xref>(b)).</p><p>Chemically, lactam is much more stable in acidic or basic conditions than lactone, due to lower ring deformation and reduced electrophilicity in the carbonyl carbon atom, because of the presence of the adjacent nitrogen atom, which is an electron donor. They are more stable under acidic conditions, such as in the stomach and in the blood stream at pH 7.4, showing superior bioavailability compared to artemisinin [<xref ref-type="bibr" rid="scirp.123424-ref22">22</xref>] [<xref ref-type="bibr" rid="scirp.123424-ref23">23</xref>] .</p><p>In this article, N-11-azaartemisinin derivatives were investigated with the following approaches: molecular electrostatic potential (MEP) [<xref ref-type="bibr" rid="scirp.123424-ref24">24</xref>] [<xref ref-type="bibr" rid="scirp.123424-ref25">25</xref>] [<xref ref-type="bibr" rid="scirp.123424-ref26">26</xref>] [<xref ref-type="bibr" rid="scirp.123424-ref27">27</xref>] , ligand-receptor interaction [<xref ref-type="bibr" rid="scirp.123424-ref28">28</xref>] [<xref ref-type="bibr" rid="scirp.123424-ref29">29</xref>] , and supervised machine learning methods [<xref ref-type="bibr" rid="scirp.123424-ref30">30</xref>] [<xref ref-type="bibr" rid="scirp.123424-ref31">31</xref>] [<xref ref-type="bibr" rid="scirp.123424-ref32">32</xref>] [<xref ref-type="bibr" rid="scirp.123424-ref33">33</xref>] . In a first moment, MEP maps were constructed, evaluated and used in the assumption to identify the key features of N-11-azaartemisisnins that are necessary for their activities and to investigate their probable interactions with a receptor through recognition in a biological process. Next, the interactions between N-11-azaartemisinins and the heme receptor were investigated and the interaction energies were correlated with the biological activities of the molecules. Subsequently, supervised machine learning methods were used to investigate the molecular properties that best classify N-11-azaartemisinins into two classes: compounds with high activity (cha) and compounds with low activity (cla), respectively, giving rise to the pattern recognition models: principal component analysis (PCA); hierarchical cluster analysis (HCA); K-nearest neighbor (KNN); soft independent modeling of class analogy (SIMCA); and stepwise discriminant analysis (SDA).</p><p>The information extracted from each step of the investigation, along with the chemical intuition, led to the design of new N-11-azaartemisinins cha that were evaluated by the models built with supervised machine learning methods previously designed to establish the most promising compounds for syntheses and biological evaluation.</p></sec><sec id="s2"><title>2. Computational Procedure</title><p>The 3D structure of artemisinin encoded in CCDC-691593 [<xref ref-type="bibr" rid="scirp.123424-ref34">34</xref>] was optimized with the method DFT/B3LYP [<xref ref-type="bibr" rid="scirp.123424-ref35">35</xref>] [<xref ref-type="bibr" rid="scirp.123424-ref36">36</xref>] /6-31G [<xref ref-type="bibr" rid="scirp.123424-ref37">37</xref>] and 6-31G* [<xref ref-type="bibr" rid="scirp.123424-ref38">38</xref>] available in the GAUSSIAN 09 software [<xref ref-type="bibr" rid="scirp.123424-ref39">39</xref>] , and the computed results were compared to experimental data from the literature [<xref ref-type="bibr" rid="scirp.123424-ref40">40</xref>] . In this procedure, the B3LYP/6-31G method was selected for the subsequent electronic structure calculations step of the research.</p><p>With the optimized 3D B3LYP/6-31G structure of artemisinin, the structures of nineteen N-11-azaaretemisinins derivatives from the literature [<xref ref-type="bibr" rid="scirp.123424-ref41">41</xref>] were constructed and optimized with the same theoretical approach. For the optimized derivatives, calculations of MEPs [<xref ref-type="bibr" rid="scirp.123424-ref24">24</xref>] [<xref ref-type="bibr" rid="scirp.123424-ref25">25</xref>] [<xref ref-type="bibr" rid="scirp.123424-ref26">26</xref>] , with subsequent obtaining of MEP maps [<xref ref-type="bibr" rid="scirp.123424-ref42">42</xref>] , and of the interaction with molecular receptor (ligand-receptor), through the AUTODOCK software [<xref ref-type="bibr" rid="scirp.123424-ref43">43</xref>] , were carried-out.</p><p>The optimized geometries of N-11-azaartemisinns also allowed calculations of molecular properties used in the chemometric step of the research to identify descriptors capable of separating these compounds into two classes: compounds with high activity (cha) and compounds with low activity (cla). Chemometric approaches were carried out with artificial intelligence methods (pattern recognition methods) [<xref ref-type="bibr" rid="scirp.123424-ref44">44</xref>] [<xref ref-type="bibr" rid="scirp.123424-ref45">45</xref>] [<xref ref-type="bibr" rid="scirp.123424-ref46">46</xref>] [<xref ref-type="bibr" rid="scirp.123424-ref47">47</xref>] [<xref ref-type="bibr" rid="scirp.123424-ref48">48</xref>] , available in the PIROUETTE [<xref ref-type="bibr" rid="scirp.123424-ref49">49</xref>] and MINITAB [<xref ref-type="bibr" rid="scirp.123424-ref50">50</xref>] softwares, respectively.</p><sec id="s2_1"><title>2.1. About the Investigated N-11-Azaartemisinis</title><p>The nineteen N-11-azaartemisinins investigated have biological activity against the K-1 strain of P. falciparum resistant to chloroquine, pyrimethamine and cycloguanil. The relative activities were obtained with the expression: relative IC<sub>50</sub> = IC<sub>50</sub> (artemisinin)/IC<sub>50</sub> (N-11-azaartemisinin) [<xref ref-type="bibr" rid="scirp.123424-ref51">51</xref>] , where IC<sub>50</sub> corresponds to 50% of the inhibitory concentration of the compounds. The following hypothesis was considered in the research: N-11-azaartemisinins with relative IC50 ≥ 0.24 correspond to cha (1-8) and N-11-azaartemisinins with relative IC50 &lt; 0.24 correspond to cla (9-19).</p><p><xref ref-type="table" rid="table1">Table 1</xref> shows the N-11-azaartemisinins (R-substituted N-carbonyl and N-sulfonyl-11-azaartemisinins derivatives) and their respective IC50’s. By inspecting the structure-activity relationship it is possible to obtain some indication of how they are correlated. The N-carbonyl derivatives 4 and 5, which have a Nitro substituent (-NO<sub>2</sub>) attached at different positions on the aromatic ring, show higher antimalarial activity than artemisinin. Derivative 6, an acylurea, is the compound with the highest activity against P. falciparum among the N-11-azaartemisinins, about 1.5 times more active than artemisinin. In the N-sulfonyl derivatives, which present monosubstituted aromatic rings (9-14), it is observed that the activity increases with the increase of the electronegativity of the substituent.</p><p>Also in <xref ref-type="table" rid="table1">Table 1</xref>, in the N-sulfonyl compounds (15 and 16), whose ring is disubstituted, derivative 15, which has two electronegative substituents (Cl and NO<sub>2</sub>), shows activity around 11 times greater than compound 16. Derivatives 12 and 13, whose only structural difference is in the position of the Nitro group attached to the ring, the change in the position of this group did not significantly affect the antimalarial activity.</p><table-wrap id="table1" ><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> N-Carbonyl and N-sulfonyl-11-azaartemisinin derivatives of the training set with their substituents and respective IC<sub>50</sub> (ng/mL) and relative IC<sub>50</sub><sup>a</sup></title></caption><table><tbody><thead><tr><th align="center" valign="middle"  colspan="5"  ><inline-formula><inline-graphic xlink:href="/html.scirp.org/file/1-7100294x6.png" xlink:type="simple"/></inline-formula><inline-formula><inline-graphic xlink:href="/html.scirp.org/file/1-7100294x5.png" xlink:type="simple"/></inline-formula> (1 to 6) (7 to 19)</th></tr></thead><tr><td align="center" valign="middle" >Compounds</td><td align="center" valign="middle" >R</td><td align="center" valign="middle" >IC<sub>50 </sub></td><td align="center" valign="middle" >Relative IC<sub>50</sub></td><td align="center" valign="middle" >Antimalarial activity</td></tr><tr><td align="center" valign="middle" >1</td><td align="center" valign="middle" >CH<sub>3</sub>CH<sub>2</sub>—</td><td align="center" valign="middle" >1.0</td><td align="center" valign="middle" >0.90</td><td align="center" valign="middle" >cha</td></tr><tr><td align="center" valign="middle" >2</td><td align="center" valign="middle" >CH<sub>3</sub>(CH<sub>2</sub>)<sub>2</sub>—</td><td align="center" valign="middle" >2.0</td><td align="center" valign="middle" >0.45</td><td align="center" valign="middle" >cha</td></tr><tr><td align="center" valign="middle" >3</td><td align="center" valign="middle" >CH<sub>3</sub>(CH<sub>2</sub>)<sub>4</sub>—</td><td align="center" valign="middle" >2.0</td><td align="center" valign="middle" >0.45</td><td align="center" valign="middle" >cha</td></tr><tr><td align="center" valign="middle" >4</td><td align="center" valign="middle" >4’-O<sub>2</sub>NC<sub>6</sub>H<sub>4</sub>—</td><td align="center" valign="middle" >0.6</td><td align="center" valign="middle" >1.5</td><td align="center" valign="middle" >cha</td></tr><tr><td align="center" valign="middle" >5</td><td align="center" valign="middle" >3’-O<sub>2</sub>NC<sub>6</sub>H<sub>4</sub>—</td><td align="center" valign="middle" >0.6</td><td align="center" valign="middle" >1.5</td><td align="center" valign="middle" >cha</td></tr><tr><td align="center" valign="middle" >6</td><td align="center" valign="middle" >4’-O<sub>2</sub>NC<sub>6</sub>H<sub>4</sub>NH—</td><td align="center" valign="middle" >0.4</td><td align="center" valign="middle" >2.25</td><td align="center" valign="middle" >cha</td></tr><tr><td align="center" valign="middle" >7</td><td align="center" valign="middle" >CH<sub>3</sub>—</td><td align="center" valign="middle" >3.2</td><td align="center" valign="middle" >0.28</td><td align="center" valign="middle" >cha</td></tr><tr><td align="center" valign="middle" >8</td><td align="center" valign="middle" >CH<sub>3</sub>CH<sub>2</sub>—</td><td align="center" valign="middle" >3.7</td><td align="center" valign="middle" >0.24</td><td align="center" valign="middle" >cha</td></tr><tr><td align="center" valign="middle" >9</td><td align="center" valign="middle" >— 4’-FC<sub>6</sub>H<sub>4</sub>—</td><td align="center" valign="middle" >8.0</td><td align="center" valign="middle" >0.11</td><td align="center" valign="middle" >cla</td></tr><tr><td align="center" valign="middle" >10</td><td align="center" valign="middle" >4’-ClC<sub>6</sub>H<sub>4</sub>—</td><td align="center" valign="middle" >17</td><td align="center" valign="middle" >0.05</td><td align="center" valign="middle" >cla</td></tr><tr><td align="center" valign="middle" >11</td><td align="center" valign="middle" >4’-CH<sub>3</sub>C<sub>6</sub>H<sub>4</sub>—</td><td align="center" valign="middle" >37</td><td align="center" valign="middle" >0.02</td><td align="center" valign="middle" >cla</td></tr><tr><td align="center" valign="middle" >12</td><td align="center" valign="middle" >4’-O<sub>2</sub>NC<sub>6</sub>H<sub>4</sub>—</td><td align="center" valign="middle" >9.1</td><td align="center" valign="middle" >0.10</td><td align="center" valign="middle" >cla</td></tr><tr><td align="center" valign="middle" >13</td><td align="center" valign="middle" >2’-O<sub>2</sub>NC<sub>6</sub>H<sub>4</sub>—</td><td align="center" valign="middle" >10</td><td align="center" valign="middle" >0.09</td><td align="center" valign="middle" >cla</td></tr><tr><td align="center" valign="middle" >14</td><td align="center" valign="middle" >3’-N&#247;CC<sub>6</sub>H<sub>4</sub>—</td><td align="center" valign="middle" >50</td><td align="center" valign="middle" >0.02</td><td align="center" valign="middle" >cla</td></tr><tr><td align="center" valign="middle" >15</td><td align="center" valign="middle" >4’-Cl-3’-O<sub>2</sub>NC<sub>6</sub>H<sub>3</sub>—</td><td align="center" valign="middle" >3.8</td><td align="center" valign="middle" >0.23</td><td align="center" valign="middle" >cla</td></tr><tr><td align="center" valign="middle" >16</td><td align="center" valign="middle" >3’,4’-(CH<sub>3</sub>O)<sub>2</sub>C<sub>6</sub>H<sub>3</sub>—</td><td align="center" valign="middle" >40</td><td align="center" valign="middle" >0.02</td><td align="center" valign="middle" >cla</td></tr><tr><td align="center" valign="middle" >17</td><td align="center" valign="middle" >4’-CH<sub>3</sub>SO<sub>2</sub>C<sub>6</sub>H<sub>4</sub>—</td><td align="center" valign="middle" >13</td><td align="center" valign="middle" >0.07</td><td align="center" valign="middle" >cla</td></tr><tr><td align="center" valign="middle" >18</td><td align="center" valign="middle" >4’-C<sub>6</sub>H<sub>5</sub>-C<sub>6</sub>H<sub>4</sub>—</td><td align="center" valign="middle" >45</td><td align="center" valign="middle" >0.02</td><td align="center" valign="middle" >cla</td></tr><tr><td align="center" valign="middle" >19</td><td align="center" valign="middle" >5’-Cl-2’-tienil</td><td align="center" valign="middle" >40</td><td align="center" valign="middle" >0.02</td><td align="center" valign="middle" >cla</td></tr></tbody></table></table-wrap><p><sup>a</sup>Relative IC<sub>50</sub> = IC<sub>50</sub> of artemisinin/IC<sub>50</sub> of derivative, where IC<sub>50</sub> corresponds to 50% of the inhibitory concentration. The following hypothesis was considered: where relative IC<sub>50</sub> ≥ 0.24 corresponds to compounds with high activity (cha) and relative IC<sub>50</sub> &lt; 0.24 corresponds to compounds with low activity (cla).</p><p>Another interesting aspect to notice in the analysis of the structure-activity relationship of the N-11-azaartemisinins in <xref ref-type="table" rid="table1">Table 1</xref> is the comparison between derivatives 4 and 12. Both have the Nitro group as a substituent on the aromatic ring in the same position. However, a biological activity is observed for compound 4 (N-carbonyl) about 23 times greater than that of compound 12 (N-sulfonyl). Derivatives 1 and 8 have the same number of carbon atoms in their chains, however, it is noted that compound 1, an N-carbonyl compound, is 4 times more active than derivative 8, an N-sulfonyl compound.</p><p>By comparing the structure-activity relationship of the N-11-azaartemisinins in <xref ref-type="table" rid="table1">Table 1</xref>, it is noted that the N-carbonyl-11-azaartemisinin derivatives are much more biologically active than the N-sulfonyl derivatives, indicating a possible contribution of carbonyl in the N-carbonyl derivatives for antimalarial activity.</p></sec><sec id="s2_2"><title>2.2. The Biological Recognition Process through Molecular Electrostatic Potential</title><p>In the biological recognition process, the receptor molecule “recognizes” the approach of another molecule with key features to promote mutual interaction. It is understood that such a recognition should typically occur when the drug (substrate) and receptor (enzyme) are in relatively considerable separation, and precede the formation of any covalent bond [<xref ref-type="bibr" rid="scirp.123424-ref26">26</xref>] .</p><p>Molecular electrostatic potential has the physical meaning of how the molecule is perceived by its surroundings. Searching through this approach, the main key features that determine the occurrence or not of a recognition is a natural behavior in research associated with this tool. Furthermore, the aforementioned tool proved to be an effective means of analyzing and elucidating recognition processes [<xref ref-type="bibr" rid="scirp.123424-ref26">26</xref>] .</p><p>MEP calculations were carried out using the approach reported by Politzer &amp; Murray (Equation (1)) [<xref ref-type="bibr" rid="scirp.123424-ref52">52</xref>] through electron density and the MEP maps obtained with the MOLEKEL software [<xref ref-type="bibr" rid="scirp.123424-ref42">42</xref>] .</p><p>V ( r ) = ∑ A Z A | R A − r | − ∫ ​ ( r ' ) d r ' | r ′ − r | (1)</p><p>where Z A is the charge on nucleus A, located at R A , and ρ ( r ) is the electronic density of the atom or molecule.</p></sec><sec id="s2_3"><title>2.3. Ligand-Receptor Interaction</title><p>The study of ligand-receptor interaction (molecular docking) investigates in detail how a small molecule (ligand) interacts in the binding region with a macromolecule (receptor), generating important information for understanding the biological activity of a given drug. In addition, it makes possible to visualize the way in which the two molecules interact and to quantify this interaction. The process begins when the structures are not yet connected, the ligand seeks its best position in the receptor’s active site, generating a certain number of conformational possibilities in the search for the best ligand-receptor anchoring [<xref ref-type="bibr" rid="scirp.123424-ref29">29</xref>] [<xref ref-type="bibr" rid="scirp.123424-ref53">53</xref>] [<xref ref-type="bibr" rid="scirp.123424-ref54">54</xref>] .</p><p>The ligand-receptor molecular recognition involves multiple steps of conformational accommodation, resulting in the most favorable mode of interaction enthalpic and entropically. Equation (2) can estimate these processes, through the Gibbs binding free energy (ΔG); which is related to the inhibition constant (K<sub>i</sub>), determined experimentally. In the Equation (2), ΔH is the enthalpy change, T is the absolute temperature, ΔS is the entropy change, and R is the universal gas constant.</p><p>Δ G = Δ H − T Δ S = R T l n K i (2)</p><p>In the molecular docking study, the heme [<xref ref-type="bibr" rid="scirp.123424-ref55">55</xref>] [<xref ref-type="bibr" rid="scirp.123424-ref56">56</xref>] was used as a receptor for artemisinin, 11-azaartemisinin, and N-11 azaartemisinins, and its 3D structure was taken from the Protein Data Bank (PDB) RCSB, 1A6M [<xref ref-type="bibr" rid="scirp.123424-ref56">56</xref>] .</p></sec><sec id="s2_4"><title>2.4. Supervised Machine Learning Methods</title><p>To identify the molecular descriptors capable of separating N-11-azaartemisinins into the cha and cla classes, respectively, supervised machine learning methods were used: Principal Component Analysis (PCA), Hierarchical Cluster Analysis (HCA), K-Nearest Neighbor method, (KNN), Soft Independent Modeling of Class Analogy (SIMCA) method [<xref ref-type="bibr" rid="scirp.123424-ref44">44</xref>] [<xref ref-type="bibr" rid="scirp.123424-ref45">45</xref>] [<xref ref-type="bibr" rid="scirp.123424-ref46">46</xref>] , and Stepwise Discriminant Analysis (SDA) [<xref ref-type="bibr" rid="scirp.123424-ref45">45</xref>] [<xref ref-type="bibr" rid="scirp.123424-ref46">46</xref>] [<xref ref-type="bibr" rid="scirp.123424-ref47">47</xref>] [<xref ref-type="bibr" rid="scirp.123424-ref48">48</xref>] . For a description of these methods, consult the cited references [<xref ref-type="bibr" rid="scirp.123424-ref44">44</xref>] [<xref ref-type="bibr" rid="scirp.123424-ref45">45</xref>] [<xref ref-type="bibr" rid="scirp.123424-ref46">46</xref>] [<xref ref-type="bibr" rid="scirp.123424-ref47">47</xref>] [<xref ref-type="bibr" rid="scirp.123424-ref48">48</xref>] .</p></sec><sec id="s2_5"><title>2.5. Calculated Molecular Properties</title><p>The molecular properties calculated and used as descriptors were steric properties: bond lengths, bond angles, and torsion angles; electronic properties: total energy (TE), ε<sub>HOMO</sub> (highest occupied molecular orbital energy), ε<sub>HOMO-1</sub> (one level below to highest occupied molecular orbital energy), ε<sub>HOMO-2</sub> (two level below to highest occupied molecular orbital energy), ε<sub>HOMO-3</sub> (three levels below to highest occupied molecular orbital energy), absolute value of ε<sub>LUMO</sub> (lowest unoccupied molecular orbital energy), absolute value of ε<sub>LUMO+1</sub> (one level above lowest unoccupied molecular orbital), absolute value of ε<sub>LUMO+2</sub> (two levels above lowest unoccupied one), absolute value of ε<sub>LUMO+3</sub> (three levels above lowest unoccupied molecular orbital); Mulliken’s electronegativity (χ = 1/2(ε<sub>HOMO</sub><sub> </sub>–<sub> </sub>ε<sub>LUMO</sub>)), molecular hardness (η = I – AE/2), where I is ionization potential and AE electron affinity; molecular softness (1/η), defined as the inverse of molecular hardness; dipole moment (μ), energy GAP (GAP = ε<sub>HOMO</sub><sub> </sub>–<sub> </sub>ε<sub>LUMO</sub>), and atomic charges on an Nth atom (Q<sub>N</sub>); physicochemical properties: molecular polarizability (POL), Molecular refractivity (MR), hydration energy (HE), partition coefficient octanol-water (log P), molecular mass, total surface area (TSA), and molecular volume (VOL).</p><p>Additionally, to represent different sources of chemical information about size, symmetry, and distribution of atoms in the molecule, holistic properties were also calculated and considered as descriptors.</p><p>All properties were considered in the most stable conformation of each molecule and the descriptors were computed to given information about the influence of steric, electronic, hydrophobic, and hydrophilic features on the antimalarial activity of the studied N-11-azaartemisinins.</p><p>The steric and electronic, physicochemical, and holistic properties were performed with the GAUSSIAN 09 [<xref ref-type="bibr" rid="scirp.123424-ref39">39</xref>] , CHEMPLUS [<xref ref-type="bibr" rid="scirp.123424-ref57">57</xref>] , and DRAGON [<xref ref-type="bibr" rid="scirp.123424-ref58">58</xref>] softwares, respectively.</p></sec></sec><sec id="s3"><title>3. Results and Discussion</title><sec id="s3_1"><title>3.1. Theoretical Geometry</title><p><xref ref-type="table" rid="table2">Table 2</xref> shows the geometry obtained with the B3LYP/6-31G, B3LYP/6-31G*, and experimental methods, and the discrepancies between the theoretical and experimental values. It can be seen that the bond lengths when compared to the literature data are very well described with both methods, with the B3LYP/6 31G* method (this work) showing a slightly better performance in the description of this geometric parameter, especially considering the importance of the distance between O<sub>1</sub> and O<sub>2</sub> in the antimalarial activity of artemisinin [<xref ref-type="bibr" rid="scirp.123424-ref59">59</xref>] [<xref ref-type="bibr" rid="scirp.123424-ref60">60</xref>] [<xref ref-type="bibr" rid="scirp.123424-ref61">61</xref>] [<xref ref-type="bibr" rid="scirp.123424-ref62">62</xref>] .</p></sec><sec id="s3_2"><title>3.2. Molecular Electrostatic Potential Maps for Artemisinin, 11-Azaartemisinin and N-11-Azaartemisinins</title><p>The literature reports the pharmacophore 1,2,4-trioxane as crucial to artemisinin activity and its derivatives [<xref ref-type="bibr" rid="scirp.123424-ref2">2</xref>] [<xref ref-type="bibr" rid="scirp.123424-ref59">59</xref>] [<xref ref-type="bibr" rid="scirp.123424-ref60">60</xref>] [<xref ref-type="bibr" rid="scirp.123424-ref61">61</xref>] [<xref ref-type="bibr" rid="scirp.123424-ref63">63</xref>] . <xref ref-type="fig" rid="fig2">Figure 2</xref> shows the 2D structures and the molecular MEP maps for artemisinin (<xref ref-type="fig" rid="fig2">Figure 2</xref>(a)) and 11-azaartemisinin (<xref ref-type="fig" rid="fig2">Figure 2</xref>(b)), respectively. In this figure, 2D structure, it can be noted that the replacement of O<sub>4</sub> (artemisinin, IC<sub>50</sub> = 0.903 ng/mL [<xref ref-type="bibr" rid="scirp.123424-ref49">49</xref>] or 0.903/0.904 = 1) by N (11-azaartemisinin, IC = 2.656 ng/mL [<xref ref-type="bibr" rid="scirp.123424-ref19">19</xref>] or 2.656/0.903 = 2.94) maintains the endoperoxide link necessary for antimalarial activity. Also in this figure, the MEP maps of the compounds show considerable similarities, with decrease in electron density in the endoperoxide region, evidenced by the decrease in the biological activity of 11-azaartemisinin; with artemisinin exhibiting minimum and maximum electrostatic potential values of −126.76 and +99.15 kcal/mol, respectively, while in 11-azaartemisinin these values are around −130.52 and 120.48 kcal/mol.</p><p>All N-11-azaartemisinins shown in <xref ref-type="table" rid="table1">Table 1</xref> (see Section 2.1. About the investigated N-11-azaartemisinis) also exhibit the endoperoxide linkage necessary for antimalarial activity. <xref ref-type="fig" rid="fig3">Figure 3</xref> shows the MEP maps for the N-11-azaartemisinins of the training set obtained by the inclusion of substituents in the N atom of the lactam function (1-19). As one can see in this figure, the MEP maps are similar to artemisinin and 11-azaartemisinin in the 1, 2, 4 trioxane ring region, with the electron density of some molecules more concentrated in this region, indicating greater biological activity. N-11-azaartemisinins are susceptible to electrophilic attack in the most negative MEP region, –130.52 to –114.21 kcal/mol, respectively.</p><table-wrap id="table2" ><label><xref ref-type="table" rid="table2">Table 2</xref></label><caption><title> Theoretical and experimental geometry of the 1,2,4-trioxane ring for artemisinin</title></caption><table><tbody><thead><tr><th align="center" valign="middle"  rowspan="2"  >Geometry<sup>a</sup></th><th align="center" valign="middle"  colspan="3"  >Methods Theoretical</th><th align="center" valign="middle"  colspan="2"  >Discrepancy (Δ)<sup>c</sup></th></tr></thead><tr><td align="center" valign="middle" >B3LYP/6-31G</td><td align="center" valign="middle" >B3LYP/6-31G* (this work)</td><td align="center" valign="middle" >Exp<sup>b</sup></td><td align="center" valign="middle" >Δ<sub>1</sub><sup> </sup></td><td align="center" valign="middle" >Δ<sub>2</sub><sup> </sup></td></tr><tr><td align="center" valign="middle" >Bond length (A)</td><td align="center" valign="middle"  colspan="5"  ></td></tr><tr><td align="center" valign="middle" >C<sub>10</sub>-O<sub>1</sub></td><td align="center" valign="middle" >1.499</td><td align="center" valign="middle" >1.455</td><td align="center" valign="middle" >1.461</td><td align="center" valign="middle" >3.8 &#215; 10<sup>−2 </sup></td><td align="center" valign="middle" >−6 &#215; 10<sup>−3</sup></td></tr><tr><td align="center" valign="middle" >O<sub>1</sub>-O<sub>2</sub></td><td align="center" valign="middle" >1.524</td><td align="center" valign="middle" >1.460</td><td align="center" valign="middle" >1.469</td><td align="center" valign="middle" >5.5 &#215; 10<sup>−2</sup></td><td align="center" valign="middle" >−9 &#215; 10<sup>−3</sup></td></tr><tr><td align="center" valign="middle" >O<sub>2</sub>-C<sub>8</sub></td><td align="center" valign="middle" >1.452</td><td align="center" valign="middle" >1.414</td><td align="center" valign="middle" >1.416</td><td align="center" valign="middle" >3.6 &#215; 10<sup>−2</sup></td><td align="center" valign="middle" >−4 &#215; 10<sup>−3 </sup></td></tr><tr><td align="center" valign="middle" >C<sub>8</sub>-O<sub>3</sub></td><td align="center" valign="middle" >1.473</td><td align="center" valign="middle" >1.441</td><td align="center" valign="middle" >1.445</td><td align="center" valign="middle" >2.8 &#215; 10<sup>−2</sup></td><td align="center" valign="middle" >−4 &#215; 10<sup>−3</sup></td></tr><tr><td align="center" valign="middle" >O<sub>3</sub>-C<sub>9</sub></td><td align="center" valign="middle" >1.425</td><td align="center" valign="middle" >1.396</td><td align="center" valign="middle" >1.379</td><td align="center" valign="middle" >4.6 &#215; 10<sup>−2</sup></td><td align="center" valign="middle" >1.7 &#215; 10<sup>−2 </sup></td></tr><tr><td align="center" valign="middle" >C<sub>9-</sub>C<sub>10</sub></td><td align="center" valign="middle" >1.538</td><td align="center" valign="middle" >1.539</td><td align="center" valign="middle" >1.523</td><td align="center" valign="middle" >1.5 &#215; 10<sup>−2 </sup></td><td align="center" valign="middle" >1.6 &#215; 10<sup>−2 </sup></td></tr><tr><td align="center" valign="middle" >C<sub>10</sub>-C<sub>5</sub></td><td align="center" valign="middle" >1.533</td><td align="center" valign="middle" >1.555</td><td align="center" valign="middle" >1.534</td><td align="center" valign="middle" >1.9 &#215; 10<sup>−2 </sup></td><td align="center" valign="middle" >2.1 &#215; 10<sup>−2 </sup></td></tr><tr><td align="center" valign="middle" >C<sub>5-</sub>C<sub>6</sub></td><td align="center" valign="middle" >1.552</td><td align="center" valign="middle" >1.548</td><td align="center" valign="middle" >1.527</td><td align="center" valign="middle" >2.5 &#215; 10<sup>−2 </sup></td><td align="center" valign="middle" >2.1 &#215; 10<sup>−2 </sup></td></tr><tr><td align="center" valign="middle" >C<sub>6-</sub>C<sub>7</sub></td><td align="center" valign="middle" >1.544</td><td align="center" valign="middle" >1.540</td><td align="center" valign="middle" >1.520</td><td align="center" valign="middle" >2.4 &#215; 10<sup>−2 </sup></td><td align="center" valign="middle" >2.0 &#215; 10<sup>−2 </sup></td></tr><tr><td align="center" valign="middle" >C<sub>7-</sub>C<sub>8</sub></td><td align="center" valign="middle" >1.544</td><td align="center" valign="middle" >1.547</td><td align="center" valign="middle" >1.510</td><td align="center" valign="middle" >3.4 &#215; 10<sup>−2 </sup></td><td align="center" valign="middle" >3.7 &#215; 10<sup>−2 </sup></td></tr><tr><td align="center" valign="middle" >Bon angle (˚)</td><td align="center" valign="middle"  colspan="5"  ></td></tr><tr><td align="center" valign="middle" >C<sub>10</sub>-O<sub>1</sub>-O<sub>2 </sub></td><td align="center" valign="middle" >111.407</td><td align="center" valign="middle" >111.609</td><td align="center" valign="middle" >111.200</td><td align="center" valign="middle" >2.07 &#215; 10<sup>−1</sup></td><td align="center" valign="middle" >4.09 &#215; 10<sup>−1 </sup></td></tr><tr><td align="center" valign="middle" >O<sub>1</sub>-O<sub>2</sub>-C<sub>8</sub></td><td align="center" valign="middle" >107.304</td><td align="center" valign="middle" >108.261</td><td align="center" valign="middle" >108.100</td><td align="center" valign="middle" >−7.96 &#215; 10<sup>−1</sup></td><td align="center" valign="middle" >1.61 &#215; 10<sup>−1</sup></td></tr><tr><td align="center" valign="middle" >O<sub>2</sub>-C<sub>8</sub>-O<sub>3</sub></td><td align="center" valign="middle" >107.738</td><td align="center" valign="middle" >108.487</td><td align="center" valign="middle" >106.600</td><td align="center" valign="middle" >1.14 &#215; 10<sup>0</sup></td><td align="center" valign="middle" >1.89 &#215; 10<sup>0</sup></td></tr><tr><td align="center" valign="middle" >C<sub>8</sub>-O<sub>3</sub>-C<sub>9</sub></td><td align="center" valign="middle" >114.996</td><td align="center" valign="middle" >114.069</td><td align="center" valign="middle" >114.200</td><td align="center" valign="middle" >7.96 &#215; 10<sup>−1</sup></td><td align="center" valign="middle" >−1.31 &#215; 10<sup>−1</sup></td></tr><tr><td align="center" valign="middle" >O<sub>3</sub>-C<sub>9</sub>-C<sub>10</sub></td><td align="center" valign="middle" >113.641</td><td align="center" valign="middle" >113.264</td><td align="center" valign="middle" >114.500</td><td align="center" valign="middle" >−8.59 &#215; 10<sup>−1</sup></td><td align="center" valign="middle" >−1.24 &#215; 10<sup>0</sup></td></tr><tr><td align="center" valign="middle" >C<sub>9</sub>-C<sub>10</sub>-O<sub>1 </sub></td><td align="center" valign="middle" >111.751</td><td align="center" valign="middle" >111.323</td><td align="center" valign="middle" >111.700</td><td align="center" valign="middle" >5.1 &#215; 10<sup>−2</sup></td><td align="center" valign="middle" >−3.77 &#215; 10<sup>−1 </sup></td></tr><tr><td align="center" valign="middle" >Dihedral angle (˚)</td><td align="center" valign="middle"  colspan="5"  ></td></tr><tr><td align="center" valign="middle" >C<sub>10</sub>-O<sub>1</sub>-O<sub>2</sub>-C<sub>8 </sub></td><td align="center" valign="middle" >46.883</td><td align="center" valign="middle" >47.915</td><td align="center" valign="middle" >47.800</td><td align="center" valign="middle" >−9.17 &#215; 10<sup>−1 </sup></td><td align="center" valign="middle" >9.3 &#215; 10<sup>−2 </sup></td></tr><tr><td align="center" valign="middle" >O<sub>1</sub>-O<sub>2</sub>-C<sub>8</sub>-O<sub>3</sub></td><td align="center" valign="middle" >−73.464</td><td align="center" valign="middle" >−73.450</td><td align="center" valign="middle" >−75.500</td><td align="center" valign="middle" >2.04 &#215; 10<sup>0</sup></td><td align="center" valign="middle" >1.55 &#215; 10<sup>0 </sup></td></tr><tr><td align="center" valign="middle" >O<sub>2</sub>-C<sub>8</sub>-O<sub>3</sub>-C<sub>9 </sub></td><td align="center" valign="middle" >34.986</td><td align="center" valign="middle" >32.892</td><td align="center" valign="middle" >36.00</td><td align="center" valign="middle" >−1.01 &#215; 10<sup>0 </sup></td><td align="center" valign="middle" >−3.11 &#215; 10<sup>0 </sup></td></tr><tr><td align="center" valign="middle" >C<sub>8</sub>-O<sub>3</sub>-C<sub>9</sub>-C<sub>10 </sub></td><td align="center" valign="middle" >26.252</td><td align="center" valign="middle" >27.351</td><td align="center" valign="middle" >25.300</td><td align="center" valign="middle" >9.52 &#215; 10<sup>−1 </sup></td><td align="center" valign="middle" >2.04 &#215; 10<sup>0 </sup></td></tr><tr><td align="center" valign="middle" >O<sub>3</sub>-C<sub>9</sub>-C<sub>10</sub>-O<sub>2 </sub></td><td align="center" valign="middle" >−51.202</td><td align="center" valign="middle" >−51.180</td><td align="center" valign="middle" >−51.300</td><td align="center" valign="middle" >9.8 &#215; 10<sup>−2 </sup></td><td align="center" valign="middle" >1.20 &#215; 10<sup>−1 </sup></td></tr><tr><td align="center" valign="middle" >C<sub>9</sub>-C<sub>10</sub>-O<sub>1</sub>-O<sub>2 </sub></td><td align="center" valign="middle" >12.765</td><td align="center" valign="middle" >11.671</td><td align="center" valign="middle" >12.700</td><td align="center" valign="middle" >6.5 &#215; 10<sup>−2 </sup></td><td align="center" valign="middle" >−1.03 &#215; 10<sup>0 </sup></td></tr></tbody></table></table-wrap><p><sup>a</sup>The atoms were labeled according to <xref ref-type="fig" rid="fig2">Figure 2</xref>. <sup>b</sup>Ref [<xref ref-type="bibr" rid="scirp.123424-ref40">40</xref>] . <sup>c</sup>Δ = Theoretical (6-31G and 6-31G* basis sets, respectively) – Experimental data.</p></sec><sec id="s3_3"><title>3.3. Interaction between Artemisinin, 11-Azaartemisinin, N-11-Azaartemisinins and the Heme Receptor</title><p>Since all N-11-azaartemisinins were derived from 11-azaartemisinin, a previous study of the interaction between artemisinin and 11-azaartemisinin with the biological receptor was performed. <xref ref-type="fig" rid="fig4">Figure 4</xref> shows the 2D structures and the respective interactions of artemisinin and 11-azaartemisinin with heme. According to this figure, the ligand-heme interaction energies for these molecules correspond to −5.24 and −6.37 kcal/mol, respectively. The d(Fe-O<sub>1</sub>) and d(Fe-O<sub>2</sub>) distances for artemisinin are equal to 2.670 and 3.827 &#197;, respectively, with d(Fe-O<sub>1</sub>) very close to the value 2.7 reported by other studies [<xref ref-type="bibr" rid="scirp.123424-ref64">64</xref>] [<xref ref-type="bibr" rid="scirp.123424-ref65">65</xref>] , reinforcing the perspective of O<sub>1</sub> preferential binding of the trioxane ring to Fe<sup>2+</sup> heme. For 11-azaartemisinin, these distances are 2.569 and 3.659 &#197;, respectively; with lower d(Fe-O<sub>1</sub>) value for 11-azaartemisinin, reflecting its higher interaction energy and lower biological activity.</p><p>In <xref ref-type="fig" rid="fig5">Figure 5</xref>, the interactions between N-11-azaartemisinins (1-19) and heme are shown. As can be seen, also in this figure, O<sub>1</sub> is preferentially oriented to Fe<sup>2+</sup>-heme in the totality of N-11-azaartemisinins. <xref ref-type="table" rid="table3">Table 3</xref> shows the values of the d(Fe-O<sub>1</sub>) and d(Fe-O<sub>2</sub>) distances and the ligand-heme interaction energies. From this table, it can be seen that d(Fe-O<sub>1</sub>) is always smaller than d(Fe-O<sub>2</sub>) in all interactions and that, in general, d(Fe-O<sub>1</sub>) has higher values for N-11-azaartemesinins cha, when compared with the corresponding cla. Also, according to <xref ref-type="table" rid="table3">Table 3</xref>, it is possible to associate, in general, higher values of d(Fe-O<sub>1</sub>) and lower values for the interaction energy of N-11-azaartemisinins cha to biological processes occurring with increased biological activity of these compounds.</p></sec><sec id="s3_4"><title>3.4. Supervised Machine Learning Methods</title><p>With the molecular properties calculated, a matrix of descriptors of dimension 19 &#215; 120 (number of N-11-azaartemisinins (lines) versus molecular properties (columns)) was constructed and the exploratory analyzes of the autoscaled data were performed with the supervised learning methods PCA and HCA. Data</p><table-wrap id="table3" ><label><xref ref-type="table" rid="table3">Table 3</xref></label><caption><title> Values of d(Fe-O<sub>1</sub>), d(Fe-O<sub>2</sub>), absolute value of the difference between d(Fe-O<sub>1</sub>) and d(Fe-O<sub>2</sub>) (Δ) and interaction energy of the ligand-heme complex for the training set</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >Compouds</th><th align="center" valign="middle" >d(Fe-O<sub>1</sub>)<sup>a</sup></th><th align="center" valign="middle" >d(Fe-O<sub>2</sub>)<sup>a</sup></th><th align="center" valign="middle" >Δ<sup>b</sup></th><th align="center" valign="middle" >Energy interaction<sup>c</sup></th></tr></thead><tr><td align="center" valign="middle" >1</td><td align="center" valign="middle" >2.675</td><td align="center" valign="middle" >3.797</td><td align="center" valign="middle" >1.05</td><td align="center" valign="middle" >−4.90</td></tr><tr><td align="center" valign="middle" >2</td><td align="center" valign="middle" >2.592</td><td align="center" valign="middle" >3.663</td><td align="center" valign="middle" >1.07</td><td align="center" valign="middle" >−4.79</td></tr><tr><td align="center" valign="middle" >3</td><td align="center" valign="middle" >2.674</td><td align="center" valign="middle" >3.832</td><td align="center" valign="middle" >1.16</td><td align="center" valign="middle" >−4.71</td></tr><tr><td align="center" valign="middle" >4</td><td align="center" valign="middle" >2.392</td><td align="center" valign="middle" >3.007</td><td align="center" valign="middle" >0.62</td><td align="center" valign="middle" >−6.17</td></tr><tr><td align="center" valign="middle" >5</td><td align="center" valign="middle" >2.370</td><td align="center" valign="middle" >3.121</td><td align="center" valign="middle" >0.75</td><td align="center" valign="middle" >−5.52</td></tr><tr><td align="center" valign="middle" >6</td><td align="center" valign="middle" >2.380</td><td align="center" valign="middle" >3.161</td><td align="center" valign="middle" >0.78</td><td align="center" valign="middle" >−5.80</td></tr><tr><td align="center" valign="middle" >7</td><td align="center" valign="middle" >2.619</td><td align="center" valign="middle" >3.714</td><td align="center" valign="middle" >1.10</td><td align="center" valign="middle" >−5.09</td></tr><tr><td align="center" valign="middle" >8</td><td align="center" valign="middle" >2.609</td><td align="center" valign="middle" >3.823</td><td align="center" valign="middle" >1.21</td><td align="center" valign="middle" >−5.96</td></tr><tr><td align="center" valign="middle" >9</td><td align="center" valign="middle" >2.407</td><td align="center" valign="middle" >2.630</td><td align="center" valign="middle" >0.22</td><td align="center" valign="middle" >−6.51</td></tr><tr><td align="center" valign="middle" >10</td><td align="center" valign="middle" >2.317</td><td align="center" valign="middle" >2.680</td><td align="center" valign="middle" >0.36</td><td align="center" valign="middle" >−6.99</td></tr><tr><td align="center" valign="middle" >11</td><td align="center" valign="middle" >2.371</td><td align="center" valign="middle" >2.507</td><td align="center" valign="middle" >0.14</td><td align="center" valign="middle" >−6.85</td></tr><tr><td align="center" valign="middle" >12</td><td align="center" valign="middle" >2.365</td><td align="center" valign="middle" >2.585</td><td align="center" valign="middle" >0.22</td><td align="center" valign="middle" >−6.63</td></tr><tr><td align="center" valign="middle" >13</td><td align="center" valign="middle" >2.247</td><td align="center" valign="middle" >2.937</td><td align="center" valign="middle" >0.69</td><td align="center" valign="middle" >−6.20</td></tr><tr><td align="center" valign="middle" >14</td><td align="center" valign="middle" >2.371</td><td align="center" valign="middle" >3.074</td><td align="center" valign="middle" >0.70</td><td align="center" valign="middle" >−5.41</td></tr><tr><td align="center" valign="middle" >15</td><td align="center" valign="middle" >2.423</td><td align="center" valign="middle" >2.613</td><td align="center" valign="middle" >0.19</td><td align="center" valign="middle" >−5.04</td></tr><tr><td align="center" valign="middle" >16</td><td align="center" valign="middle" >2.445</td><td align="center" valign="middle" >2.566</td><td align="center" valign="middle" >0.12</td><td align="center" valign="middle" >−6.49</td></tr><tr><td align="center" valign="middle" >17</td><td align="center" valign="middle" >2.442</td><td align="center" valign="middle" >2.610</td><td align="center" valign="middle" >0.17</td><td align="center" valign="middle" >−5.04</td></tr><tr><td align="center" valign="middle" >18</td><td align="center" valign="middle" >2.371</td><td align="center" valign="middle" >2.560</td><td align="center" valign="middle" >0.19</td><td align="center" valign="middle" >−5.83</td></tr><tr><td align="center" valign="middle" >19</td><td align="center" valign="middle" >2.331</td><td align="center" valign="middle" >2.860</td><td align="center" valign="middle" >0.53</td><td align="center" valign="middle" >−6.85</td></tr></tbody></table></table-wrap><p><sup>a</sup>Values in &#197;. <sup>b Δ = | d ( Fe-O 1 ) − d ( Fe-O 2 ) | </sup>. <sup>c</sup>Values in kcal/mol.</p><p>compression was performed considering the Pearson r correlation coefficient &gt; 0.82 and, consequently, low correlation between two descriptors, with one of them being randomly excluded from the matrix for theoretically describing the same property. With this procedure, a considerable reduction in the size of the initial matrix was verified and, then, the PCA exploratory method was applied.</p><sec id="s3_4_1"><title>3.4.1. PCA Model</title><p>After several attempts, the 11-N-azaartemisinins were separated, with the help of three variables, into two classes: cha class and cla class. <xref ref-type="table" rid="table4">Table 4</xref> shows the descriptor matrix selected in the PCA for the training set and respective values of the biological activities and the correlation matrix between the descriptors. As can be seen, the correlation between the descriptors is less than 0.642.</p><p>The molecular properties responsible for the separation of the cha and cla classes were: ε<sub>LUMO+1</sub>, TSA, and the distance between carbon 6 and carbon 5 atoms, d(C<sub>6</sub>-C<sub>5</sub>) of the molecules, respectively. The separation is done at PC1 and explains 89% of the total information, with PC1 and PC2 retaining 70% and 19% of this information, respectively. According to <xref ref-type="table" rid="table4">Table 4</xref>, in general, N-11-azaarrtemisinins of the cha class exhibit lower values for ε<sub>LUMO+1</sub> combined with lower values for d(C<sub>6</sub>-C<sub>5</sub>) and TSA compared to those of the cla class.</p><p><xref ref-type="fig" rid="fig6">Figure 6</xref> shows the plots of scores (a) and loadings (b) and the dendrogram (c) obtained with PCA and HCA, respectively, for N-11-azaartemisinins (training set). In <xref ref-type="fig" rid="fig6">Figure 6</xref>, the N-11-azaartemisinins of the cha class (1-8) are located to the left, <xref ref-type="fig" rid="fig6">Figure 6</xref>(a), due to the displacement in this direction produced by the properties ε<sub>LUMO+1</sub> and TSA, while the N-11 azaartemisinins of the cla class (9-19) are shifted to the right of the same figure due to the action of the property d(C<sub>5</sub>-C<sub>6</sub>), <xref ref-type="fig" rid="fig6">Figure 6</xref>(b).</p><p><xref ref-type="table" rid="table5">Table 5</xref> shows the loadings matrix for the selected descriptors. According to this table, it is possible to classify new N-11-azaartemisinins with cha using Equation (3), reaffirming the information previously extracted from <xref ref-type="table" rid="table4">Table 4</xref>, i.e., new N-11-azaartemisinins can be classified as cha combining lower values for ε<sub>LUMO+1</sub>, d(C<sub>6</sub>-C<sub>5</sub>), and TSA, respectively.</p><p>PC 1 = 0.543 ε LUMO+1 + 0.614 d ( C 6 -C 5 ) + 0.573 TSA (3)</p><table-wrap id="table4" ><label><xref ref-type="table" rid="table4">Table 4</xref></label><caption><title> Matrix of descriptors selected in the PCA of the training set with their respective values</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >Compounds</th><th align="center" valign="middle" >ε<sub>LUMO+1</sub><sup>a</sup><sup> </sup></th><th align="center" valign="middle" >d(C<sub>6</sub>-C<sub>5</sub>)<sup>b </sup></th><th align="center" valign="middle" >TSA<sup>c</sup><sup> </sup></th><th align="center" valign="middle" >Relative IC<sub>50</sub><sup> </sup></th><th align="center" valign="middle" >Antimalarial activity</th></tr></thead><tr><td align="center" valign="middle" >1</td><td align="center" valign="middle" >19.15</td><td align="center" valign="middle" >1.550</td><td align="center" valign="middle" >526.1</td><td align="center" valign="middle" >0.90</td><td align="center" valign="middle" >cha</td></tr><tr><td align="center" valign="middle" >2</td><td align="center" valign="middle" >20.44</td><td align="center" valign="middle" >1.551</td><td align="center" valign="middle" >529.2</td><td align="center" valign="middle" >0.45</td><td align="center" valign="middle" >cha</td></tr><tr><td align="center" valign="middle" >3</td><td align="center" valign="middle" >20.44</td><td align="center" valign="middle" >1.551</td><td align="center" valign="middle" >610.1</td><td align="center" valign="middle" >0.45</td><td align="center" valign="middle" >cha</td></tr><tr><td align="center" valign="middle" >4</td><td align="center" valign="middle" >39.01</td><td align="center" valign="middle" >1.551</td><td align="center" valign="middle" >604.4</td><td align="center" valign="middle" >1.50</td><td align="center" valign="middle" >cha</td></tr><tr><td align="center" valign="middle" >5</td><td align="center" valign="middle" >49.52</td><td align="center" valign="middle" >1.551</td><td align="center" valign="middle" >602.9</td><td align="center" valign="middle" >1.50</td><td align="center" valign="middle" >cha</td></tr><tr><td align="center" valign="middle" >6</td><td align="center" valign="middle" >30.90</td><td align="center" valign="middle" >1.5505</td><td align="center" valign="middle" >618.4</td><td align="center" valign="middle" >2.25</td><td align="center" valign="middle" >cha</td></tr><tr><td align="center" valign="middle" >7</td><td align="center" valign="middle" >23.18</td><td align="center" valign="middle" >1.551</td><td align="center" valign="middle" >513.3</td><td align="center" valign="middle" >0.28</td><td align="center" valign="middle" >cha</td></tr><tr><td align="center" valign="middle" >8</td><td align="center" valign="middle" >22.57</td><td align="center" valign="middle" >1.551</td><td align="center" valign="middle" >541.6</td><td align="center" valign="middle" >0.24</td><td align="center" valign="middle" >cha</td></tr><tr><td align="center" valign="middle" >9</td><td align="center" valign="middle" >32.45</td><td align="center" valign="middle" >1.553</td><td align="center" valign="middle" >585.3</td><td align="center" valign="middle" >0.11</td><td align="center" valign="middle" >cla</td></tr><tr><td align="center" valign="middle" >10</td><td align="center" valign="middle" >36.75</td><td align="center" valign="middle" >1.553</td><td align="center" valign="middle" >605.2</td><td align="center" valign="middle" >0.05</td><td align="center" valign="middle" >cla</td></tr><tr><td align="center" valign="middle" >11</td><td align="center" valign="middle" >27.55</td><td align="center" valign="middle" >1.553</td><td align="center" valign="middle" >608.2</td><td align="center" valign="middle" >0.02</td><td align="center" valign="middle" >cla</td></tr><tr><td align="center" valign="middle" >12</td><td align="center" valign="middle" >56.10</td><td align="center" valign="middle" >1.553</td><td align="center" valign="middle" >613.5</td><td align="center" valign="middle" >0.10</td><td align="center" valign="middle" >cla</td></tr><tr><td align="center" valign="middle" >13</td><td align="center" valign="middle" >55.13</td><td align="center" valign="middle" >1.553</td><td align="center" valign="middle" >592.9</td><td align="center" valign="middle" >0.09</td><td align="center" valign="middle" >cla</td></tr><tr><td align="center" valign="middle" >14</td><td align="center" valign="middle" >48.95</td><td align="center" valign="middle" >1.553</td><td align="center" valign="middle" >611.0</td><td align="center" valign="middle" >0.02</td><td align="center" valign="middle" >cla</td></tr><tr><td align="center" valign="middle" >15</td><td align="center" valign="middle" >60.22</td><td align="center" valign="middle" >1.553</td><td align="center" valign="middle" >630.9</td><td align="center" valign="middle" >0.24</td><td align="center" valign="middle" >cla</td></tr><tr><td align="center" valign="middle" >16</td><td align="center" valign="middle" >23.55</td><td align="center" valign="middle" >1.553</td><td align="center" valign="middle" >663.4</td><td align="center" valign="middle" >0.02</td><td align="center" valign="middle" >cla</td></tr><tr><td align="center" valign="middle" >17</td><td align="center" valign="middle" >48.86</td><td align="center" valign="middle" >1.553</td><td align="center" valign="middle" >649.1</td><td align="center" valign="middle" >0.07</td><td align="center" valign="middle" >cla</td></tr><tr><td align="center" valign="middle" >18</td><td align="center" valign="middle" >35.99</td><td align="center" valign="middle" >1.553</td><td align="center" valign="middle" >687.0</td><td align="center" valign="middle" >0.02</td><td align="center" valign="middle" >cla</td></tr><tr><td align="center" valign="middle" >19</td><td align="center" valign="middle" >46.26</td><td align="center" valign="middle" >1.553</td><td align="center" valign="middle" >599.3</td><td align="center" valign="middle" >0.02</td><td align="center" valign="middle" >cla</td></tr><tr><td align="center" valign="middle" >Descriptor</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >ε<sub>LUMO+1</sub></td><td align="center" valign="middle" ></td><td align="center" valign="middle" >0.565</td><td align="center" valign="middle" >0.436</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >d(C<sub>6</sub>-C<sub>5</sub>)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" >0.641</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr></tbody></table></table-wrap><p><sup>a</sup>Values in kcal/mol. <sup>b</sup>Values in &#197;. <sup>c</sup>Values in &#197;<sup>2</sup>.<sub> </sub></p><table-wrap id="table5" ><label><xref ref-type="table" rid="table5">Table 5</xref></label><caption><title> Variable matrix for PC1, PC2 and PC3</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >Variable</th><th align="center" valign="middle" >PC1</th><th align="center" valign="middle" >PC2</th><th align="center" valign="middle" >PC3</th></tr></thead><tr><td align="center" valign="middle" >ε<sub>LUMO+1</sub></td><td align="center" valign="middle" >0.543</td><td align="center" valign="middle" >−0.785</td><td align="center" valign="middle" >−0.298</td></tr><tr><td align="center" valign="middle" >d(C<sub>6</sub>-C<sub>5</sub>)</td><td align="center" valign="middle" >0.614</td><td align="center" valign="middle" >0.129</td><td align="center" valign="middle" >0.779</td></tr><tr><td align="center" valign="middle" >TSA</td><td align="center" valign="middle" >0.573</td><td align="center" valign="middle" >0.606</td><td align="center" valign="middle" >−0.552</td></tr><tr><td align="center" valign="middle" >Variance</td><td align="center" valign="middle" >70%</td><td align="center" valign="middle" >19%</td><td align="center" valign="middle" >11%</td></tr></tbody></table></table-wrap></sec><sec id="s3_4_2"><title>3.4.2. HCA Model</title><p><xref ref-type="fig" rid="fig6">Figure 6</xref>(c) shows the dendrogram obtained with the HCA, incremental method, for the training set N-11-azaartemisinins. According to this figure, N-11-azaartemisinins are distributed in two main clusters. The cluster on the left, corresponding to N-11-azaartemisinins with cha, which is formed by two clusters, namely: A and B. Cluster A consists of N-carbonyl and N-sulfonyl derivatives with alkyl substituents of one to three carbons in the R position (<xref ref-type="table" rid="table1">Table 1</xref>). For these N-11-azaartemisinins, the increasing of the number of carbons in the chain produced a decrease in the biological activity. In cha class, these N-11-azaartemisinins are not among the most efficient compounds against malaria and have lower TSA and d(C<sub>6</sub>-C<sub>5</sub>) and lower values for ε<sub>LUMO+1</sub>. Cluster B is formed by N-11 azaartemisinins among the most active compounds with cha. Structurally, all azaartemisinins have an aromatic ring (4, 5, and 6) as substituents in R, except for derivative 3, which has an alkyl chain with 5 carbons, being the largest aliphatic chain among all the N-11 azaartemisinins investigated. The N-11-azaartemisinins 4 and 5 are N-carbonyl whose the only difference between them is in the position of the nitro group attached to the aromatic ring in R. In the cha class, they show the highest TSA values and lower than those with cla.</p><p>The cluster on the right in <xref ref-type="fig" rid="fig6">Figure 6</xref>(c) is also made up of two smaller clusters, C and D. All the N-11-azaartemisinins in cluster C (9, 10 and 11) are N-sulfonyls that have a monosubstituted aromatic ring in the R position 4, differing only in the substituents used, namely: Fluorine (F), Chlorine (Cl) and methyl (Me), respectively. In comparison with one of the N-11-azaartemisinin with cha (4), an N-carbonyl with the same substitution in R by a monosubstituted aromatic ring in position 4, but with a different substituent (nitro), shows a great increase in the biological activity, confirming that N-carbonyls present better results as antimalarial and suggesting that the presence of the nitro group also contributes to this better performance. In cluster C, all N-11-azaartemisinins have the highest TSA in the training set.</p><p>In cluster D, which contains N-11-azaartemisinins with lower biological potency, it can be noted that all compounds are N-sulfonyl derivatives with monosubstitution (12, 13, and 14) and disubstitution (15 and 16) in the aromatic ring, two rings isolates (18) and 5-Chloro-thienyl (19) in R. In this cluster, N-11-azaartemisinins show the highest values for ε<sub>LUMO+1</sub> and d(C<sub>6</sub>-C<sub>5</sub>) of the training set.</p><p>Finally, it can be reported that the HCA results confirm the PCA.</p></sec><sec id="s3_4_3"><title>3.4.3. KNN Model</title><p>The KNN study was developed with the variables ε<sub>LUMO+1</sub>, d(C<sub>6</sub>-C<sub>5</sub>) and TSA selected by the PCA and HCA for the N-11 azaartemisins of the training set. <xref ref-type="table" rid="table6">Table 6</xref> shows the results of classification using this method. The correct information was 100% for 1 KNN, 2 KNN, 3 KNN and 4 KNN, that is, all derivatives were correctly classified within the predicted classes, indicating that the classifications (1 KNN, 2 KNN, 3 KNN and 4 KNN) obtained with the selected descriptors provide good predictive capacity. The KNN model was built with the four nearest neighbors [<xref ref-type="bibr" rid="scirp.123424-ref66">66</xref>] .</p><table-wrap id="table6" ><label><xref ref-type="table" rid="table6">Table 6</xref></label><caption><title> Classification of the training set with the KNN method</title></caption><table><tbody><thead><tr><th align="center" valign="middle" ></th><th align="center" valign="middle"  colspan="5"  >Incorrectly classified compounds</th></tr></thead><tr><td align="center" valign="middle" >Class</td><td align="center" valign="middle" >Number of Compounds</td><td align="center" valign="middle" >1 KNN</td><td align="center" valign="middle" >2 KNN</td><td align="center" valign="middle" >3 KNN</td><td align="center" valign="middle" >4 KNN</td></tr><tr><td align="center" valign="middle" >cha</td><td align="center" valign="middle" >8</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >0</td></tr><tr><td align="center" valign="middle" >cla</td><td align="center" valign="middle" >11</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >0</td></tr><tr><td align="center" valign="middle" >Total</td><td align="center" valign="middle" >19</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >0</td></tr><tr><td align="center" valign="middle"  colspan="2"  >Percentage of correct information</td><td align="center" valign="middle" >100</td><td align="center" valign="middle" >100</td><td align="center" valign="middle" >100</td><td align="center" valign="middle" >100</td></tr></tbody></table></table-wrap></sec><sec id="s3_4_4"><title>3.4.4. SIMCA Model</title><p>The SIMCA model was built with the selected descriptors in PCA, HCA and KNN and three PCs. <xref ref-type="table" rid="table7">Table 7</xref> shows the classification matrix obtained by the SIMCA method. The correct information in the classification was 100%. Furthermore, the SIMCA model shows good discriminating power, evidenced by high distances and high residuals between classes, <xref ref-type="fig" rid="fig7">Figure 7</xref>.</p></sec><sec id="s3_4_5"><title>3.4.5. SDA Model</title><p>The SDA approach provided the achievement of discriminant functions with the variables ε<sub>LUMO+1</sub>, d(C<sub>6</sub>-C<sub>5</sub>) and TSA showing significant contributions in the classification methodology of N-11-azaartemisinins. Equations (4a) and (4b) show these functions for the classes with cha and cla, respectively:</p><p>chaclass : − 0.063 ε LUMO+1 − 19.401 d ( C 6 -C 5 ) + 0.749 TSA − 10.519 (4a)</p><p>claclass : + 0.046 ε LUMO+ 1 + 14.110 d ( C 6 -C 5 ) − 0.545 TSA − 5.564 (4b)</p><p>With the discriminant functions and the values of the selected variables for the N-11-azaartemisinins, a classification matrix was obtained for the training set. <xref ref-type="table" rid="table8">Table 8</xref> shows the SDA classification matrix with the respective percentage of correct answers.</p><p>The reliability of the SDA model was evaluated through the cross-validation test, the leave-one-out technique, which consisted of omitting an N-11-azaaratemisinin from the data set and building the discriminant functions with the other samples. Subsequently, this omitted N-11-azaartemisinin was classified with the generated discriminant functions, and the procedure was repeated until the last N-11 azaartemisinin in the data set was omitted. <xref ref-type="table" rid="table9">Table 9</xref> shows the SDA classification matrix using the cross-validation procedure.</p><p>With the SDA model, an allocation rule was established when new N-11-azaartemisinins with cha or cla investigated: 1) initially calculate, for the new molecule, the value of the properties used in the construction of the model, 2) consider the autoscaled values of these molecular properties (descriptors) in the discriminant functions, Equations 4(a) and 4(b), and 3) verify which discriminant function has the highest value. The new N-11-azaartemisinin is cha if it is related to the discriminant functions of the cha class and vice versa.</p><p>Once the properties selected in the study with supervised machine learning methods (PCA, HCA, KNN, SIMCA and SDA) proved to be more important in the description of the antimalarial activity of N-11-azaartemisinins, some considerations that lead to the understanding of the behavior of the class cha become relevant. In this context, in <xref ref-type="table" rid="table4">Table 4</xref> it can be seen that, in general, the N-11-azaartemisinins of the cha class have ε<sub>LUMO+1</sub> values lower than those of the N-11-azaartemisinins of the cla class. Conditioning to the LUMO+1 of the N-11-azaartemisinins the possibility of interaction with the heme receptor orbital that presents the greatest contribution of electron density [<xref ref-type="bibr" rid="scirp.123424-ref67">67</xref>] , an electron transfer reaction will be important in the mechanism of action of ligands (cha class) in the biological process.</p><p>The bond length is a geometric parameter related to the steric availability of the atoms involved in the bond [<xref ref-type="bibr" rid="scirp.123424-ref68">68</xref>] . According to <xref ref-type="table" rid="table4">Table 4</xref>, the N-11-azaartemisinins of the cha class have d(C<sub>6</sub>-C<sub>5</sub>) values lower than those of the cla class. This may be indicative of the importance of the steric distribution of atoms of the N-11-azaartemisinins of the cha class in their possible mechanism of action in the biological process.</p><table-wrap id="table7" ><label><xref ref-type="table" rid="table7">Table 7</xref></label><caption><title> Classification matrix obtained with the SIMCA method</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >Class</th><th align="center" valign="middle" >Number of Compounds</th><th align="center" valign="middle" >SIMCA Classification</th></tr></thead><tr><td align="center" valign="middle" >cha</td><td align="center" valign="middle" >08</td><td align="center" valign="middle" >08</td></tr><tr><td align="center" valign="middle" >cla</td><td align="center" valign="middle" >11</td><td align="center" valign="middle" >11</td></tr><tr><td align="center" valign="middle" >Total</td><td align="center" valign="middle" >19</td><td align="center" valign="middle" >19</td></tr><tr><td align="center" valign="middle"  colspan="2"  >Percentage of correct information</td><td align="center" valign="middle" >100</td></tr></tbody></table></table-wrap><table-wrap id="table8" ><label><xref ref-type="table" rid="table8">Table 8</xref></label><caption><title> Classification matrix of the training set compounds with SDA</title></caption><table><tbody><thead><tr><th align="center" valign="middle"  rowspan="2"  >Class</th><th align="center" valign="middle"  rowspan="2"  >Number of compounds</th><th align="center" valign="middle"  colspan="2"  >Correct classification</th></tr></thead><tr><td align="center" valign="middle" >cha</td><td align="center" valign="middle" >cla</td></tr><tr><td align="center" valign="middle" >cha</td><td align="center" valign="middle" >8</td><td align="center" valign="middle" >8</td><td align="center" valign="middle" >0</td></tr><tr><td align="center" valign="middle" >cla</td><td align="center" valign="middle" >11</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >11</td></tr><tr><td align="center" valign="middle" >Total</td><td align="center" valign="middle" >19</td><td align="center" valign="middle" >8</td><td align="center" valign="middle" >11</td></tr><tr><td align="center" valign="middle"  colspan="2"  >Percentage of correct information</td><td align="center" valign="middle" >100</td><td align="center" valign="middle" >100</td></tr></tbody></table></table-wrap><table-wrap id="table9" ><label><xref ref-type="table" rid="table9">Table 9</xref></label><caption><title> Classification matrix using SDA with Cross-Validation</title></caption><table><tbody><thead><tr><th align="center" valign="middle"  rowspan="2"  >Class</th><th align="center" valign="middle"  rowspan="2"  >Number of compounds</th><th align="center" valign="middle"  colspan="2"  >Correct classification</th></tr></thead><tr><td align="center" valign="middle" >cha</td><td align="center" valign="middle" >cla</td></tr><tr><td align="center" valign="middle" >cha</td><td align="center" valign="middle" >8</td><td align="center" valign="middle" >8</td><td align="center" valign="middle" >0</td></tr><tr><td align="center" valign="middle" >cla</td><td align="center" valign="middle" >11</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >11</td></tr><tr><td align="center" valign="middle" >Total</td><td align="center" valign="middle" >19</td><td align="center" valign="middle" >8</td><td align="center" valign="middle" >11</td></tr><tr><td align="center" valign="middle"  colspan="2"  >Percentage of correct information</td><td align="center" valign="middle" >100</td><td align="center" valign="middle" >100</td></tr></tbody></table></table-wrap><p>The TSA property determines the solvent accessible area of a molecule. <xref ref-type="table" rid="table4">Table 4</xref> shows that N-11-azaartemisinins belonging to the cha class exhibit lower values for TSA when compared to those of the cla class. This is an indication that in biological processes involving N-11-azaartemisinins and heme, hydrophilic interactions may be important in the mechanism of action of these molecules.</p></sec><sec id="s3_4_6"><title>3.4.6. Combining MEP, Ligand-Receptor Interaction and Supervised Machine Learning Methods in the Design of New N-11-Azaartemisinins</title><p>The insights gained from studies of MEP, ligand-receptor interaction and supervised machine learning methods, together with chemical intuition, enabled the design of sixteen new N-11-azaartemisinins (prediction set) potentially active against P. falciparum. <xref ref-type="table" rid="table1">Table 1</xref>0 shows the N-11-azaartemisinins of the prediction set.</p><p>The models obtained with supervised machine learning methods were applied to the prediction set and <xref ref-type="table" rid="table1">Table 1</xref>1 shows the results of this application. In this table, N-11-azaartemisinins 20-26 and 31-35 were considered as cha by all models, while N-11-azaartemisinins 27 and 30 were reported as cla by these models. N-11-azaartemisinins 28 and 29 were classified as cha by the KNN model and cla by the PCA, HCA and SDA models, with no classification by the SIMCA model.</p><p>The results of the application of models built with supervised machine learning methods to the prediction set show twelve N-11-azaartemisinins: 20, 21, 22, 23, 24, 25, 26, 31, 32, 33, 34, and 35 potentially in the cha class as the most promising for future syntheses and biological assays, which will be able to validate the methodology proposed in this research for the design of these new N-11-azaartemisinins with activity against P. falciparum.</p><p>In <xref ref-type="table" rid="table1">Table 1</xref>2, the molecular properties of the N-11-azaartemisinins of the prediction set are reported. In this table, similar to <xref ref-type="table" rid="table4">Table 4</xref>, it can be scrutinized that ε<sub>LUMO+1</sub>, d(C<sub>6</sub>-C<sub>5</sub>) and TSA, in general, present lower values for cha, when compared to cla.</p><p><xref ref-type="table" rid="table1">Table 1</xref>3 shows the values of d(Fe-O<sub>1</sub>), d(Fe-O<sub>2</sub>) distances, absolute values of the differences between d(Fe-O<sub>1</sub>) and d(Fe-O<sub>2</sub>), and interaction energies of the ligand-heme complex for the N-11-azaartemisinins in the prediction set.</p><table-wrap id="table10" ><label><xref ref-type="table" rid="table1">Table 1</xref>0</label><caption><title> Classification matrix using SDA with Cross-Validation</title></caption><table><tbody><thead><tr><th align="center" valign="middle"  colspan="2"  ><inline-formula><inline-graphic xlink:href="/html.scirp.org/file/1-7100294x49.png" xlink:type="simple"/></inline-formula><inline-formula><inline-graphic xlink:href="/html.scirp.org/file/1-7100294x48.png" xlink:type="simple"/></inline-formula> (20 to 26) (27 to 35)</th></tr></thead><tr><td align="center" valign="middle" >Compounds</td><td align="center" valign="middle" >R</td></tr><tr><td align="center" valign="middle" >20</td><td align="center" valign="middle" >4’-HOCC<sub>6</sub>H<sub>4</sub>NH—</td></tr><tr><td align="center" valign="middle" >21</td><td align="center" valign="middle" >4’-NCC<sub>6</sub>H<sub>4</sub>NH—</td></tr><tr><td align="center" valign="middle" >22</td><td align="center" valign="middle" >4’-F<sub>3</sub>CC<sub>6</sub>H<sub>4</sub>NH—</td></tr><tr><td align="center" valign="middle" >23</td><td align="center" valign="middle" >4’-HOOCC<sub>6</sub>H<sub>4</sub>NH—</td></tr><tr><td align="center" valign="middle" >24</td><td align="center" valign="middle" >4’-HOCC<sub>6</sub>H<sub>4</sub>—</td></tr><tr><td align="center" valign="middle" >25</td><td align="center" valign="middle" >4’-H<sub>2&#173;</sub>NOCC<sub>6</sub>H<sub>4</sub>—</td></tr><tr><td align="center" valign="middle" >26</td><td align="center" valign="middle" >4’-HOOCC<sub>6</sub>H<sub>4</sub>—</td></tr><tr><td align="center" valign="middle" >27</td><td align="center" valign="middle" >3’-HOCC<sub>6</sub>H<sub>4</sub>—</td></tr><tr><td align="center" valign="middle" >28</td><td align="center" valign="middle" >α-O<sub>2</sub>NC<sub>10</sub>H<sub>6</sub>—</td></tr><tr><td align="center" valign="middle" >29</td><td align="center" valign="middle" >α-HOCC<sub>10</sub>H<sub>6</sub>—</td></tr><tr><td align="center" valign="middle" >30</td><td align="center" valign="middle" >α-HOCC<sub>10</sub>H<sub>6</sub>—</td></tr><tr><td align="center" valign="middle" >31</td><td align="center" valign="middle" >HOCCHCHCH<sub>2</sub>—</td></tr><tr><td align="center" valign="middle" >32</td><td align="center" valign="middle" >HOCCHCH—</td></tr><tr><td align="center" valign="middle" >33</td><td align="center" valign="middle" >HOCNHCHCH—</td></tr><tr><td align="center" valign="middle" >34</td><td align="center" valign="middle" >CH<sub>3</sub>CHCOOCHCH—</td></tr><tr><td align="center" valign="middle" >35</td><td align="center" valign="middle" >HOCCHCHNH—</td></tr></tbody></table></table-wrap></sec><sec id="s3_4_7"><title>3.4.7. MEP Maps, Ligand-Heme Interaction and Position of the LUMO+1 Orbital for Some N-11-Azaartemisinins from the Training and Prediction Sets</title><p><xref ref-type="fig" rid="fig8">Figure 8</xref> reports 2D structure (a), MEP maps (b), ligand-heme interaction (c), and position of the LUMO+1 orbital (d) in N-11-azaartemisinins cha (6 and 11) of the set of training and cla (20 and 27) of the prediction set. Scrutinizing this figure, it can be noticed that the MEP (b) maps of the N-11-azaartemisinins cha in the two sets of molecules studied (11 and 27, respectively) are similar to artemisinin (<xref ref-type="fig" rid="fig2">Figure 2</xref>(a)), 11 azaartemisinin (<xref ref-type="fig" rid="fig2">Figure 2</xref>(b)) and N-11-azaartemisinins (<xref ref-type="fig" rid="fig3">Figure 3</xref>) in the region of the endoperoxide group. In <xref ref-type="fig" rid="fig8">Figure 8</xref>(a) and <xref ref-type="fig" rid="fig8">Figure 8</xref>(b), the N-11-azaartemisinins can be attacked by nucleophiles in this region. Furthermore, as can be seen in <xref ref-type="fig" rid="fig8">Figure 8</xref>(b), the MEPs of N-11-azaartemisinins cha (11 and 27) present more negative values (−129.27 and −124.25 kcal/mol) when compared to the values (−114.21 and −121.74 kcal/mol) of N-11-azaatemisinins cla (6 and 20).</p><table-wrap id="table11" ><label><xref ref-type="table" rid="table1">Table 1</xref>1</label><caption><title> Results of applying PR models to the prediction set</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >Compounds</th><th align="center" valign="middle" >PCA model</th><th align="center" valign="middle" >HCA model</th><th align="center" valign="middle" >KNN model</th><th align="center" valign="middle" >SIMCAmodel</th><th align="center" valign="middle" >SDA model</th></tr></thead><tr><td align="center" valign="middle" >20</td><td align="center" valign="middle" >cha</td><td align="center" valign="middle" >cha</td><td align="center" valign="middle" >cha</td><td align="center" valign="middle" >cha</td><td align="center" valign="middle" >cha</td></tr><tr><td align="center" valign="middle" >21</td><td align="center" valign="middle" >cha</td><td align="center" valign="middle" >cha</td><td align="center" valign="middle" >cha</td><td align="center" valign="middle" >cha</td><td align="center" valign="middle" >cha</td></tr><tr><td align="center" valign="middle" >22</td><td align="center" valign="middle" >cha</td><td align="center" valign="middle" >cha</td><td align="center" valign="middle" >cha</td><td align="center" valign="middle" >cha</td><td align="center" valign="middle" >cha</td></tr><tr><td align="center" valign="middle" >23</td><td align="center" valign="middle" >cha</td><td align="center" valign="middle" >cha</td><td align="center" valign="middle" >cha</td><td align="center" valign="middle" >cha</td><td align="center" valign="middle" >cha</td></tr><tr><td align="center" valign="middle" >24</td><td align="center" valign="middle" >cha</td><td align="center" valign="middle" >cha</td><td align="center" valign="middle" >cha</td><td align="center" valign="middle" >cha</td><td align="center" valign="middle" >cha</td></tr><tr><td align="center" valign="middle" >25</td><td align="center" valign="middle" >cha</td><td align="center" valign="middle" >cha</td><td align="center" valign="middle" >cha</td><td align="center" valign="middle" >cha</td><td align="center" valign="middle" >cha</td></tr><tr><td align="center" valign="middle" >26</td><td align="center" valign="middle" >cha</td><td align="center" valign="middle" >cha</td><td align="center" valign="middle" >cha</td><td align="center" valign="middle" >cha</td><td align="center" valign="middle" >cha</td></tr><tr><td align="center" valign="middle" >27</td><td align="center" valign="middle" >cla</td><td align="center" valign="middle" >cla</td><td align="center" valign="middle" >cla</td><td align="center" valign="middle" >cla</td><td align="center" valign="middle" >cla</td></tr><tr><td align="center" valign="middle" >28</td><td align="center" valign="middle" >cla</td><td align="center" valign="middle" >cla</td><td align="center" valign="middle" >cla</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >cla</td></tr><tr><td align="center" valign="middle" >29</td><td align="center" valign="middle" >cla</td><td align="center" valign="middle" >cla</td><td align="center" valign="middle" >cha</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >cla</td></tr><tr><td align="center" valign="middle" >30</td><td align="center" valign="middle" >cla</td><td align="center" valign="middle" >cla</td><td align="center" valign="middle" >cla</td><td align="center" valign="middle" >cla</td><td align="center" valign="middle" >cla</td></tr><tr><td align="center" valign="middle" >31</td><td align="center" valign="middle" >cha</td><td align="center" valign="middle" >cha</td><td align="center" valign="middle" >cha</td><td align="center" valign="middle" >cha</td><td align="center" valign="middle" >cha</td></tr><tr><td align="center" valign="middle" >32</td><td align="center" valign="middle" >cha</td><td align="center" valign="middle" >cha</td><td align="center" valign="middle" >cha</td><td align="center" valign="middle" >cha</td><td align="center" valign="middle" >cha</td></tr><tr><td align="center" valign="middle" >33</td><td align="center" valign="middle" >cha</td><td align="center" valign="middle" >cha</td><td align="center" valign="middle" >cha</td><td align="center" valign="middle" >cha</td><td align="center" valign="middle" >cha</td></tr><tr><td align="center" valign="middle" >34</td><td align="center" valign="middle" >cha</td><td align="center" valign="middle" >cha</td><td align="center" valign="middle" >cha</td><td align="center" valign="middle" >cha</td><td align="center" valign="middle" >cha</td></tr><tr><td align="center" valign="middle" >35</td><td align="center" valign="middle" >cha</td><td align="center" valign="middle" >cha</td><td align="center" valign="middle" >cha</td><td align="center" valign="middle" >cha</td><td align="center" valign="middle" >cha</td></tr></tbody></table></table-wrap><table-wrap id="table12" ><label><xref ref-type="table" rid="table1">Table 1</xref>2</label><caption><title> Molecular properties of the N-11-azartemisinins in the prediction set</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >Compounds</th><th align="center" valign="middle" >ε<sub>LUMO+1</sub></th><th align="center" valign="middle" >d(C<sub>6</sub>-C<sub>5</sub>)<sup>b</sup></th><th align="center" valign="middle" >TSA<sup>c</sup></th></tr></thead><tr><td align="center" valign="middle" >20</td><td align="center" valign="middle" >27.22</td><td align="center" valign="middle" >1.551</td><td align="center" valign="middle" >614.5</td></tr><tr><td align="center" valign="middle" >21</td><td align="center" valign="middle" >28.10</td><td align="center" valign="middle" >1.550</td><td align="center" valign="middle" >615.6</td></tr><tr><td align="center" valign="middle" >22</td><td align="center" valign="middle" >28.16</td><td align="center" valign="middle" >1.550</td><td align="center" valign="middle" >626.5</td></tr><tr><td align="center" valign="middle" >23</td><td align="center" valign="middle" >26.51</td><td align="center" valign="middle" >1.551</td><td align="center" valign="middle" >627.4</td></tr><tr><td align="center" valign="middle" >24</td><td align="center" valign="middle" >26.98</td><td align="center" valign="middle" >1.551</td><td align="center" valign="middle" >601.4</td></tr><tr><td align="center" valign="middle" >25</td><td align="center" valign="middle" >25.44</td><td align="center" valign="middle" >1.551</td><td align="center" valign="middle" >618.3</td></tr><tr><td align="center" valign="middle" >26</td><td align="center" valign="middle" >25.56</td><td align="center" valign="middle" >1.551</td><td align="center" valign="middle" >614.9</td></tr><tr><td align="center" valign="middle" >27</td><td align="center" valign="middle" >53.00</td><td align="center" valign="middle" >1.553</td><td align="center" valign="middle" >646.3</td></tr><tr><td align="center" valign="middle" >28</td><td align="center" valign="middle" >55.73</td><td align="center" valign="middle" >1.553</td><td align="center" valign="middle" >642.7</td></tr><tr><td align="center" valign="middle" >29</td><td align="center" valign="middle" >51.36</td><td align="center" valign="middle" >1.553</td><td align="center" valign="middle" >636.7</td></tr><tr><td align="center" valign="middle" >30</td><td align="center" valign="middle" >51.26</td><td align="center" valign="middle" >1.553</td><td align="center" valign="middle" >605.5</td></tr><tr><td align="center" valign="middle" >31</td><td align="center" valign="middle" >42.22</td><td align="center" valign="middle" >1.551</td><td align="center" valign="middle" >605.5</td></tr><tr><td align="center" valign="middle" >32</td><td align="center" valign="middle" >51.14</td><td align="center" valign="middle" >1.551</td><td align="center" valign="middle" >567.8</td></tr><tr><td align="center" valign="middle" >33</td><td align="center" valign="middle" >35.36</td><td align="center" valign="middle" >1.551</td><td align="center" valign="middle" >595.3</td></tr><tr><td align="center" valign="middle" >34</td><td align="center" valign="middle" >50.50</td><td align="center" valign="middle" >1.551</td><td align="center" valign="middle" >624.8</td></tr><tr><td align="center" valign="middle" >35</td><td align="center" valign="middle" >26.76</td><td align="center" valign="middle" >1.551</td><td align="center" valign="middle" >572.9</td></tr></tbody></table></table-wrap><p><sup>a</sup>Values in kcal/mol. <sup>b</sup>Values in &#197;. <sup>c</sup>Values in &#197;<sup>2</sup></p><table-wrap id="table13" ><label><xref ref-type="table" rid="table1">Table 1</xref>3</label><caption><title> Values of d(Fe-O<sub>1</sub>), d(Fe-O<sub>2</sub>), absolute value of the difference between d(Fe-O<sub>1</sub>) and d(Fe-O<sub>2</sub>), and interaction energy of the ligand-heme complex for the N-11-azaartemisinins in the prediction set</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >Compounds</th><th align="center" valign="middle" >d(Fe-O<sub>1</sub>)<sup>a</sup></th><th align="center" valign="middle" >d(Fe-O<sub>2</sub>)<sup>a</sup></th><th align="center" valign="middle" >Δ<sup>b</sup></th><th align="center" valign="middle" >Energy interaction<sup>c</sup></th></tr></thead><tr><td align="center" valign="middle" >20</td><td align="center" valign="middle" >2.336</td><td align="center" valign="middle" >3.105</td><td align="center" valign="middle" >0.77</td><td align="center" valign="middle" >−7.14</td></tr><tr><td align="center" valign="middle" >21</td><td align="center" valign="middle" >2.319</td><td align="center" valign="middle" >2.910</td><td align="center" valign="middle" >0.60</td><td align="center" valign="middle" >−7.45</td></tr><tr><td align="center" valign="middle" >22</td><td align="center" valign="middle" >2.359</td><td align="center" valign="middle" >3.164</td><td align="center" valign="middle" >0.80</td><td align="center" valign="middle" >−7.08</td></tr><tr><td align="center" valign="middle" >23</td><td align="center" valign="middle" >2.397</td><td align="center" valign="middle" >3.113</td><td align="center" valign="middle" >0.71</td><td align="center" valign="middle" >−6.57</td></tr><tr><td align="center" valign="middle" >24</td><td align="center" valign="middle" >2.351</td><td align="center" valign="middle" >2.984</td><td align="center" valign="middle" >0.63</td><td align="center" valign="middle" >−5.45</td></tr><tr><td align="center" valign="middle" >25</td><td align="center" valign="middle" >2.544</td><td align="center" valign="middle" >2.737</td><td align="center" valign="middle" >1.07</td><td align="center" valign="middle" >−7.21</td></tr><tr><td align="center" valign="middle" >26</td><td align="center" valign="middle" >2.387</td><td align="center" valign="middle" >2.890</td><td align="center" valign="middle" >0.50</td><td align="center" valign="middle" >−6.14</td></tr><tr><td align="center" valign="middle" >27</td><td align="center" valign="middle" >2.350</td><td align="center" valign="middle" >3.160</td><td align="center" valign="middle" >1.00</td><td align="center" valign="middle" >−5.12</td></tr><tr><td align="center" valign="middle" >28</td><td align="center" valign="middle" >2.395</td><td align="center" valign="middle" >2.583</td><td align="center" valign="middle" >0.19</td><td align="center" valign="middle" >−6.68</td></tr><tr><td align="center" valign="middle" >29</td><td align="center" valign="middle" >2.480</td><td align="center" valign="middle" >2.660</td><td align="center" valign="middle" >0.18</td><td align="center" valign="middle" >−5.33</td></tr><tr><td align="center" valign="middle" >30</td><td align="center" valign="middle" >2.510</td><td align="center" valign="middle" >2.620</td><td align="center" valign="middle" >0.11</td><td align="center" valign="middle" >−7.31</td></tr><tr><td align="center" valign="middle" >31</td><td align="center" valign="middle" >2.389</td><td align="center" valign="middle" >3.139</td><td align="center" valign="middle" >0.75</td><td align="center" valign="middle" >−5.92</td></tr><tr><td align="center" valign="middle" >32</td><td align="center" valign="middle" >2.511</td><td align="center" valign="middle" >3.600</td><td align="center" valign="middle" >1.09</td><td align="center" valign="middle" >−5.77</td></tr><tr><td align="center" valign="middle" >33</td><td align="center" valign="middle" >2.524</td><td align="center" valign="middle" >3.635</td><td align="center" valign="middle" >1.11</td><td align="center" valign="middle" >−5.39</td></tr><tr><td align="center" valign="middle" >34</td><td align="center" valign="middle" >2.458</td><td align="center" valign="middle" >3.483</td><td align="center" valign="middle" >1.03</td><td align="center" valign="middle" >−5.83</td></tr><tr><td align="center" valign="middle" >35</td><td align="center" valign="middle" >2.540</td><td align="center" valign="middle" >3.670</td><td align="center" valign="middle" >1.13</td><td align="center" valign="middle" >−6.42</td></tr></tbody></table></table-wrap><p><sup>a</sup>Values in &#197;. <sup>b Δ = | d ( Fe-O 1 ) − d ( Fe-O 2 ) | </sup>. <sup>c</sup>Values in kcal/mol.</p><p>Still in <xref ref-type="fig" rid="fig8">Figure 8</xref>(c), as one can see, the N-11-azaartemisinins-heme interaction of the cha class, in the training (6) and prediction (20) sets, are also similar to those verified in artemisinin (<xref ref-type="fig" rid="fig4">Figure 4</xref>(a)), 11-azaartemisinin (<xref ref-type="fig" rid="fig4">Figure 4</xref>(b)) and N-11-azaartemisinins (<xref ref-type="fig" rid="fig3">Figure 3</xref>). The distances d(Fe-O<sub>1</sub>) and d(Fe-O<sub>2</sub>) in the N-11-azaartemisinins in <xref ref-type="fig" rid="fig8">Figure 8</xref>(c), class cha, lie between 2.370 and 2.675 &#197;, 3.007 and 3.832 &#197;, respectively. For the N-11-azaartemisinins, cla class, these distances are, respectively, 2.247 and 2.445 &#197;, 2.507 and 3.074 &#197;.</p><p>The distinction between the cha and cla classes can be evidenced when the LUMO+1 orbitals are compared, as shown in <xref ref-type="fig" rid="fig8">Figure 8</xref>(d), where one can see representative N-11-azaartemisinins, cha (6) and cla (11), from the set of training, and N-11 azaartemisinins, cha (20) and cla (27), from the prediction set. The LUMO+1 orbital lobes in N-11 azaartemisinins cha are positioned primarily on the atoms of the 1,2,4-trioxane ring. The lobes in all these compounds are directed to the possible position of heme, indicating the importance of the interaction with the delocalized heme system. N-11-azaartemisinins cla exhibit LUMO+1 orbital lobes concentrated in some atoms of the substituents.</p></sec></sec></sec><sec id="s4"><title>4. Conclusions</title><p>For the investigation carried out for N-11-azaartemisinins, the approximation base set B3LYP/6-31* was indicated as the most suitable in the preliminary study with geometric parameters of artemisinin.</p><p>For N-11-azaartemisinins, the MEP maps are similar to artemisinin and 11-azaartemisinin in the 1,2,4-trioxane ring region, with the electron density of some molecules more concentrated in this region, indicating greater biological activity. N-11-azaartemisinins are susceptible to electrophilic attacks in the most negative MEP region, –130.52 to –114.21 kcal/mol, respectively.</p><p>The interactions between N-11-azaartemisinins (1-19) and heme in their entirety occur preferentially orienting Fe<sup>2+</sup> to heme. The distance d(Fe-O<sub>1</sub>) is smaller than d(Fe-O<sub>2</sub>) in all ligand-heme interactions and, in general, d(Fe-O1) has higher values for N-11-azaartemesinins cha, when compared to N-11-azaartemisinins cla. It is also verified, in general, higher values of d(Fe-O<sub>1</sub>) and lower values for the interaction energy in N-11-azaartemisinins cha for biological processes that occur with increased biological activity of these compounds.</p><p>The application of supervised machine learning methods (PCA, HCA, KNN, SIMCA, and SDA) led to the separation of N-11-azaartemisinins into classes cha and cla, with properties ε<sub>LUMO+1</sub>, d(C6-C5), and TSA being responsible for classification. Each of these properties can be associated with relevant aspects in the mechanism of action of the ligands of the cha class, that is:</p><p>1) the LUMO+1 orbital of the N-11-azaartemisinins can interact with the heme orbital that presents the greatest contribution to the electron density, characterizing the importance of the charge transfer reaction in the action of the ligands of the cha class in the biological process;</p><p>2) the d(C<sub>6</sub>-C<sub>5</sub>) property may indicate the importance of the steric distribution of atoms of the N-11-azaartemisinins of the cha class in the biological process;</p><p>3) the TSA property may indicate that in the biological process involving N-11-azaartemisinins and heme, hydrophobic interactions may be relevant in the mechanism of action of molecules of the cha class.</p><p>The insights resulting from the investigation of N-11-azaartemisinins with MEP, ligand-receptor interaction, supervised machine learning methods, and chemical intuition, led to the design of 16 new molecules (20-35). The application of the models obtained with the supervised learning methods (PCA, HCA, KNN, SIMCA and SDA) to this prediction set showed 12 new N-11-azaartemisinins (20-26, and 31-35) promising for syntheses (in progress in the Synthesis Laboratory of the Federal University of Par&#225;) and biological evaluation, which may contribute to the validation of the results of this investigation in the future.</p></sec><sec id="s5"><title>Acknowledgements</title><p>The authors would like to thank the Swiss Center for Scientific Computing for use of MOLEKEL software. We also employed computing facilities at the Laborat&#243;rio de Qu&#237;micaTe&#243;rica e Computacional (LQTC) at the Universidade Federal do Par&#225; (UFPA).</p></sec><sec id="s6"><title>Conflicts of Interest</title><p>The authors declare no conflicts of interest regarding the publication of this paper.</p></sec><sec id="s7"><title>Cite this paper</title><p>de Castro, J.S.O., Pinheiro, J.C., dos Santos de Morais, S.S., Bitencourt, H.R., de Figueiredo, A.F., dos Santos, M.A.B., dos Santos Gil, F. and Pinheiro, A.C.B. (2023) Design of N-11-Azaartemisinins Potentially Active against Plasmodium falciparum by Combined Molecular Electrostatic Potential, Ligand-Receptor Interaction and Models Built with Supervised Machine Learning Methods. Journal of Biophysical Chemistry, 14, 1-29. https://doi.org/10.4236/jbpc.2023.141001</p></sec></body><back><ref-list><title>References</title><ref id="scirp.123424-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">World Health Organization (2021) World Malaria Report 2021.  
https://www.who.int/teams/global-malaria-programme/reports/world-malaria-report-2021</mixed-citation></ref><ref id="scirp.123424-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">World Health Organization (2018) Artemisinin Resistance and Artemisinin-Based Combination Therapy Efficacy: Status Report. 
 https://apps.who.int/iris/handle/10665/274362</mixed-citation></ref><ref id="scirp.123424-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Ferreira, M.U. and Castro, M.C. (2016) Challenges for Malaria Elimination in Brazil. Malaria Journal, 15, 284. https://doi.org/10.1186/s12936-016-1335-1</mixed-citation></ref><ref id="scirp.123424-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Frohlich, T., Karagoz, A.C., Reiter, C. and Tsogoeva, S.B. (2016) Artemisinin-Derived Dimers: Potent Antimalarial and Anti-Cancer Agents. Journal of Medicinal Chemistry, 59, 7360-7388. https://doi.org/10.1021/acs.jmedchem.5b01380</mixed-citation></ref><ref id="scirp.123424-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Abbasitabar, F. and Zare-Shahabadi, V. (2017) QSAR Study of Artemisinin Analogues as Antimalarial Drugs by Neural Network and Replacement Method. Drug Research (Stuttg), 67, 476-484. https://doi.org/10.1055/s-0043-108553</mixed-citation></ref><ref id="scirp.123424-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Yamansarova, E.Y., Kazakova, D.V., Medvedeva, N.I., Khusnutdinovaa, E.F., Kazakovaa, O.B., Legostaevaa, Y.V., Ishmuratova, G.Y., Huongc, L.M.H., Hac, T.T.H., Huongc, D.T. and Suponitskyd, K.Y. (2018) Synthesis and Antimalarial Activity of 3’-Trifluoromethylated 1,2,4-Trioxolanes and 1,2,4,5-Tetraoxane Based on Deoxycholic Acid. Steroids, 129, 17-23. https://doi.org/10.1016/j.steroids.2017.11.008</mixed-citation></ref><ref id="scirp.123424-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Tse, E.G., Korsik, M. and Todd, M.H. (2019) The Past, Present and Future of Anti-Malarial Medicines. Malaria Journal, 18, 93.  
https://doi.org/10.1186/s12936-019-2724-z</mixed-citation></ref><ref id="scirp.123424-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Yousefnejad, S., Mahboubifar, M. and Eskandari, R. (2019) Quantitative Structure-Activity Relationship to Predict the Anti-Malarial Activity in a Set of New Imidazolopiperazines Based on Artificial Neural Networks. Malaria Journal, 18, 310.  
https://doi.org/10.1186/s12936-019-2941-5</mixed-citation></ref><ref id="scirp.123424-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Palla, D., Antoniou, A.I., Baltas, M., Menendez, C., Grellier, P., Mouray, E. and Athanassopoulos, C.M. (2020) Synthesis and Antiplasmodial Activity of Novel Fosmidomycin Derivatives and Conjugates with Artemisinin and Aminochloroquinoline. Molecules, 25, 4858. https://doi.org/10.3390/molecules25204858</mixed-citation></ref><ref id="scirp.123424-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Chang, C.M. (2020) A Quantitative Structure-Activity Relationship Study on the Antimalarial Activities of 4-Aminoquinoline, Febrifugine and Artemisinin Compounds. International Journal Quantitative Structure-Property Relationships, 5, 63-79. https://doi.org/10.4018/IJQSPR.2020010104</mixed-citation></ref><ref id="scirp.123424-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Nguyen, P.T.V., Dat, T.V., Mizukami, S.M., Nguyen, D.L.H., Mosaddeque, F., Kim, S. N., Nguyen, D.H.B., Dinh, O.T., Vo, T.L., Nguyen, G.L.T., Duong, C.Q., Mizuta, S., Dao Ngoc Hien Tam, D.N.H., Truong, M.P.T., Huy, N.T. and Hirayama, K. (2021) 2D-Quantitative Structure-Activity Relationships Model Using PLS Method for Anti-Malarial Activities of Anti-Haemozoin Compounds. Malaria Journal, 20, 264. https://doi.org/10.1186/s12936-021-03775-2</mixed-citation></ref><ref id="scirp.123424-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Patel, O.P.S., Beteck, R.M. and Legoabe, L.J. (2021) Exploration of Artemisinin Derivatives and Synthetic Peroxides in Antimalarial Drug Discovery Research. European Journal of Medicinal Chemistry, 213, Article ID: 113193.  
https://doi.org/10.1016/j.ejmech.2021.113193</mixed-citation></ref><ref id="scirp.123424-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Jahan, M., Leon, F., Fronczek, F.R., Elokely, K.M, Rimoldi, J., Khan, S.I. and Avery, M.A. (2021) Structure-Activity Relationships of the Antimalarial Agent Artemisinin 10. Synthesis and Antimalarial Activity of Enantiomers of rac-5β-Hydroxy-D-Secoartemisinin and Analogs: Implications Regarding the Mechanism of Action. Molecules, 26, 4163. https://www.mdpi.com/1420-3049/26/14/4163 
https://doi.org/10.3390/molecules26144163</mixed-citation></ref><ref id="scirp.123424-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Tam, D.N.H., Tawfk G.M., El Qushayri, A.E., Mehyar, G.M., Istanbuly, S., Karimzadeh, S., Tu, V.L., Tiwari, R., Dat, T.V., Nguyen, P.T.V., Hirayama, K. and Tien Huy, N.T. (2020) Correlation between Anti-Malarial and Anti-Haemozoin Activities of Anti-Malarial Compounds. Malaria Journal, 19, 298.  
https://doi.org/10.1186/s12936-020-03370-x</mixed-citation></ref><ref id="scirp.123424-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Bansal, M., Uapadhyay, C., Poonam, Kumar, S. and Rathi, B. (2021) Phthalimide Analogs for Antimalarial Drug Discovery. RSC Medicinal Chemistry, 12, 1854-1867. https://doi.org/10.1039/D1MD00244A</mixed-citation></ref><ref id="scirp.123424-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Pal, K., Raza, M.K., Legac, J., Rahman, M.A., Manzoor, S., Rosenthal, P.J. and Hoda, N. (2021) Design, Synthesis Crystal Structure and Anti-Plasmodial Evaluation of Tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidine Derivatives. RSC Medicinal Chemistry 12, 970-981. https://doi.org/10.1039/D1MD00038A</mixed-citation></ref><ref id="scirp.123424-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Brito, D., Marquez, E., Rosas, F. and Rosas, E. (2022) Predicting New Potential Antimalarial Compounds by Using Zagreb Topological Indices. AIP Advances, 12, Article No. 04507. https://doi.org/10.1063/5.0089325</mixed-citation></ref><ref id="scirp.123424-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">Harmse, R., Wong, H.N., Smit, F., Haynes, R.K. and N’Da, D.D. (2015) The Case for Development of 11-Aza-Artemisinins for Malaria. Current Medicinal Chemistry, 22, 3607-3630. https://doi.org/10.2174/0929867322666150729115752</mixed-citation></ref><ref id="scirp.123424-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">Harmse, R., Coertzen, D., Wong, H.N., Smit, F.J., van der Watt, M.E., Reader, J., Nondaba, S.H., Birkholtz, L.-M., Haynes, R.K. and N’D, D.D. (2017) Activities of 11-Azaartemisinin and N-Sulfonyl Derivatives against Asexual and Transmissible Malaria Parasites. Chemistry Medicinal Chemistry, 12, 2086-2093.  
https://doi.org/10.1002/cmdc.201700599</mixed-citation></ref><ref id="scirp.123424-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">Nisar, M., Haynes, R.K., Sung, H.H. and Williams, I.D. (2017) Mechanochemical Conversion of 11-Azaartemisinin into Pharmaceutical Cocrystals with Improved Solubility. Mechanochemical Conversion of 11-Azaartemisinin into Pharmaceutical Cocrystals with Improved Solubility. Acta Crystallographica, A73, a268.  
https://doi.org/10.1107/S0108767317097367</mixed-citation></ref><ref id="scirp.123424-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">Kumaria, A., Karnataka, M., Singhb, D., Shankarb, R., Jatc, J.L., Sharmad, S., Yadavd, D., Shrivastavae, R. and Vermaa, V.P. (2019) Current Scenario of Artemisinin and Its Analogues for Antimalarial Activity. European Journal of Medicinal Chemistry, 163, 804-829. https://doi.org/10.1016/j.ejmech.2018.12.007</mixed-citation></ref><ref id="scirp.123424-ref22"><label>22</label><mixed-citation publication-type="other" xlink:type="simple">Torok, D., Ziffer, H., Meshnick, S.R., Pan, X.-Q. and Ager, A. (1995) Syntheses and Antimalarial Activities of N-Substituted ll-Azaartemisinins. Journal of Medicinal Chemistry, 38, 5045-5050. https://doi.org/10.1021/jm00026a012</mixed-citation></ref><ref id="scirp.123424-ref23"><label>23</label><mixed-citation publication-type="other" xlink:type="simple">Bach, R.D. and Dmitrenko, O. (2005) The Effect of Carbonyl Substitution on the Strain Energy of Small Ring Compounds and Their Six-Member Ring Reference Compounds. The Journal of American Chemical Society, 128, 4598-4611.  
https://doi.org/10.1021/ja055086g</mixed-citation></ref><ref id="scirp.123424-ref24"><label>24</label><mixed-citation publication-type="other" xlink:type="simple">Bonaccorsi, R., Scrocco, E. and Tomasi, J. (1970) Molecular SCF Calculations for the Ground State of Some Three-Membered Ring Molecules: (CH2)3, (CH2)2NH2, (CH2)2NH2+, (CH2)2O, (CH2)2S, (CH)2CH2, and N2CH2. The Journal of Chemical Physics, 52, 5270. https://doi.org/10.1063/1.1672775</mixed-citation></ref><ref id="scirp.123424-ref25"><label>25</label><mixed-citation publication-type="book" xlink:type="simple">Scrocco, E. and Tomasi, J. (2005) The Electrostatic Molecular Potential as a Tool for the Interpretation of Molecular Properties. In: Davison, A. and Dewar, M.J.S., Eds., New Concepts II, Topics in Current Chemistry, Vol. 42. Springer, Berlin, 95-170.</mixed-citation></ref><ref id="scirp.123424-ref26"><label>26</label><mixed-citation publication-type="other" xlink:type="simple">Politzer, P. and Truhlar, G. (1981) Chemical Applications of Atomic and Molecular Electrostatic Potentials. Plenum Press, New York.  
https://doi.org/10.1007/978-1-4757-9634-6</mixed-citation></ref><ref id="scirp.123424-ref27"><label>27</label><mixed-citation publication-type="other" xlink:type="simple">Politzer, P., Laurence, P.R. and Jayasuriya, K. (1985) Molecular Electrostatic Potentials: An Effective Tool for the Elucidation of Biochemical Phenomena. Environmental Health Perspectives, 61, 191-202. https://doi.org/10.1289/ehp.8561191</mixed-citation></ref><ref id="scirp.123424-ref28"><label>28</label><mixed-citation publication-type="other" xlink:type="simple">Pinzi, L. and Rastelli, G. (2019) Molecular Docking: Shiffting Paradigms in Drug Discovery. International Journal of Molecular Sciences, 20, 4331.  
https://doi.org/10.3390/ijms20184331</mixed-citation></ref><ref id="scirp.123424-ref29"><label>29</label><mixed-citation publication-type="book" xlink:type="simple">Stanzione, F., Giangreco, I. and Cole, J.C. (2021) Use of Molecular Docking Computational Tools in Drug Discovery. In: Witty, D.R. and Cox, B., Eds., Progress in Medicinal Chemistry, Elsevier, New York, 273-343.  
https://doi.org/10.1016/bs.pmch.2021.01.004</mixed-citation></ref><ref id="scirp.123424-ref30"><label>30</label><mixed-citation publication-type="other" xlink:type="simple">Jurs, P.C., Kowalski, B.R. and Isenhour, T.L. (1969) Investigation of Combined Patterns from Diverse Analytical Data Using Computerized Learning Machines. Analytical Chemistry, 41, 1949-1953. https://doi.org/10.1021/ac50159a027</mixed-citation></ref><ref id="scirp.123424-ref31"><label>31</label><mixed-citation publication-type="other" xlink:type="simple">Zhao, S. (2021) Prediction of Protein Expression and Growth Rates by Supervised Machine Learning. Natural Science, 13, 301-330.  
https://doi.org/10.4236/ns.2021.138025</mixed-citation></ref><ref id="scirp.123424-ref32"><label>32</label><mixed-citation publication-type="other" xlink:type="simple">Livingstone, D.J. (1991) Pattern Recognition Methods in Rational Drug Design. Methods in Enzymology, 203, 613-638.  
https://doi.org/10.1016/0076-6879(91)03032-C</mixed-citation></ref><ref id="scirp.123424-ref33"><label>33</label><mixed-citation publication-type="book" xlink:type="simple">Varmuza, K. (2018) Methods for Multivariate Data Analysis. In: Engel, T. and Gasteiger, J., Eds., Chemoinformatics: Basic Concepts and Methods, Wiley-VCH, Weinheim, 339-437.</mixed-citation></ref><ref id="scirp.123424-ref34"><label>34</label><mixed-citation publication-type="other" xlink:type="simple">Allen, F.H. (2002) The Cambridge Structural Database: A Quarter of a Million Crystal Structures and Rising. Acta Crystallographica B, 58, 380-388.  
https://doi.org/10.1107/S0108768102003890</mixed-citation></ref><ref id="scirp.123424-ref35"><label>35</label><mixed-citation publication-type="other" xlink:type="simple">Becke, A.D. (1993) Density-Functional Thermochemistry. III. The Role of Exact Exchange. The Journal of Chemical Physics, 98, 5648-5652.  
https://doi.org/10.1063/1.464913</mixed-citation></ref><ref id="scirp.123424-ref36"><label>36</label><mixed-citation publication-type="other" xlink:type="simple">Lee, C., Yang, W. and Parr, R.G. (1988) Development of the Colic-Salvetti Correlation-Energy Formula into a Functional of the Electron Density. Physical Review B, 37, 785-789. https://doi.org/10.1103/PhysRevB.37.785</mixed-citation></ref><ref id="scirp.123424-ref37"><label>37</label><mixed-citation publication-type="other" xlink:type="simple">Binkley, J.S., Pople, J.A. and Hehre, W.J. (1980) Self-Consistent Molecular Orbital Methods. 21. Small Split-Valence Basis Sets for First-Row Elements. Journal of the American Chemical Society, 102, 939-947. https://doi.org/10.1021/ja00523a008</mixed-citation></ref><ref id="scirp.123424-ref38"><label>38</label><mixed-citation publication-type="other" xlink:type="simple">Hehre, W.J. (1976) Ab Initio Molecular Orbital Theory. Accounts of Chemical Research, 9, 399-406. https://doi.org/10.1021/ar50107a003</mixed-citation></ref><ref id="scirp.123424-ref39"><label>39</label><mixed-citation publication-type="other" xlink:type="simple">Frisch, M.J., Trucks, G.W., Schlegel, H.B., Scuseria, G.E., Robb, M.A., Cheeseman, J. R., Montgomery, J. A., Vreven, T., Kudin, K.N., Burant, J.C., Millam, J.M., Iyengar, S.S., Tomasi, J., Barone, V., Mennucci, B., Cossi, M., Scalmani, G., Rega, N., Petersson, G.A., Nakatsuji, H., Hada, M., Ehara, M., Toyota, K., Fukuda, R., Hasegawa, J., Ishida, M., Nakajima, T., Honda, Y., Kitao, O., Nakai, H., Klene, M., Li, X., Knox, J.E., Hratchian, H.P., Cross, J.B., Bakken, V., Adamo, C., Jaramillo, J., Gomperts, R., Stratmann, R. E., Yazyev, O., Austin, A.J., Cammi, R., Pomelli, C., Ochterski, J.W., Ayala, P.Y., Morokuma, K., Voth, G.A., Salvador, P., Dannenberg, J.J., Zakrzewski, V.G., Dapprich, S., Daniels, A.D., Strain, M.C., Farkas, O., Malick, D.K., Rabuck, A.D., Raghavachari, K., Foresman, J.B., Ortiz, J.V., Cui, O., Baboul, A.G., Clifford, S., Cioslowski, J., Stefanov, B.B., Liu, G., Liashenko, A., Piskorz, P., Komaromi, I., Martin, R.L., Fox, D.J., Keith, T., Al-laham, M.A., Peng, C.Y., Nanayakkara, A., Challacombe, M., Gill, P.M.W., Johnson, B., Chen, W., Wong, M.W., Gonzalez, C. and Pople, J.A. (1998) Gaussian 98, Revision A.6. Gaussian, Inc., Pittsburgh.</mixed-citation></ref><ref id="scirp.123424-ref40"><label>40</label><mixed-citation publication-type="other" xlink:type="simple">Lisgarten, J.N., Potter, B.S., Bantuzeko, C. and Palmer, R.A. (1998) Structure, Absolute Configuration, and Conformation of the Antimalarial Compound, Artemisinin. Journal of Chemical Crystallography, 28, 539-543.  
https://doi.org/10.1023/A:1023244122450</mixed-citation></ref><ref id="scirp.123424-ref41"><label>41</label><mixed-citation publication-type="other" xlink:type="simple">Haynes, R.K., Wong, H.-N., Lee, K.-W., Lung, C.-M., Shek, L.Y., Williams, I.D., Croft, S.L., Vivas, L., Rattray, L., Stewart, L., Wong, V.K.W. and Ko, B.C.B. (2007) Preparation of N-Sulfonyl- and N-Carbonyl-11-Azaartemisinins with Greatly Enhanced Thermal Stabilities: In Vitro Antimalarial Activities. Chemistry Medicinal Chemistry, 2, 1464-1472. https://doi.org/10.1002/cmdc.200700065</mixed-citation></ref><ref id="scirp.123424-ref42"><label>42</label><mixed-citation publication-type="other" xlink:type="simple">Flukiger, P., Luthi, H.P., Portmann, S. and Weber, J. (2000-2001) Molekel. Swiss Center for Scientific Computing, Mano.</mixed-citation></ref><ref id="scirp.123424-ref43"><label>43</label><mixed-citation publication-type="other" xlink:type="simple">Goodsell, D.S., Morris, G.M. and Olson, A.J. (1996) Automated Docking of Flexible Ligands: Applications of AutoDock. Journal of Molecular Recognition, 9, 1-5.  
https://doi.org/10.1002/(SICI)1099-1352(199601)9:1&lt;1::AID-JMR241&gt;3.0.CO;2-6</mixed-citation></ref><ref id="scirp.123424-ref44"><label>44</label><mixed-citation publication-type="other" xlink:type="simple">Beebe, K.R., Pell, R.J. and Seasholtz, M.B. (1998) Chemometrics: A Practical Guide. Wiley &amp; Sons, New York.</mixed-citation></ref><ref id="scirp.123424-ref45"><label>45</label><mixed-citation publication-type="other" xlink:type="simple">Oliveira, L.F.S., Cordeiro, H.C., Brito, H.G., Pinheiro, A.C.B., Santos, M.A.B., Bitencourt, H.R., Figueiredo, A.F., Araújo, J.J.O., Gil, F.S., Farias, M.S., Barbosa, J.P. and Pinheiro, J.C. (2021) Molecular Electrostatic Potential and Pattern Recognition Models to Design Potentially Active Pentamidine Derivatives against Trypanosoma brucei Rhodesiense. Research, Society and Development, 10, e261101220207.  
https://doi.org/10.33448/rsd-v10i12.20207</mixed-citation></ref><ref id="scirp.123424-ref46"><label>46</label><mixed-citation publication-type="other" xlink:type="simple">Araújo, J.J.O., de Miranda, R.M., Castro, J.S.O., Figueiredo, A.F., Pinheiro, A.C.B., Santos Morais, S.S., Santos, M.A.B., Pinheiro, A.L.R., Gil, F.S., Bitencourt, H.R., Alves, G.N.R. and Pinheiro, J.C. (2023) Designing Artemisinins with Antimalarial Potential, Combining Molecular Electrostatic Potential, Ligand-Heme Interaction and Multivariate Models. Computational Chemistry, 11, 1-23.  
https://doi.org/10.4236/cc.2023.111001</mixed-citation></ref><ref id="scirp.123424-ref47"><label>47</label><mixed-citation publication-type="other" xlink:type="simple">Johnson, R.A. and Wichem, D.W. (1992) Applied Multivariate Statistical Analysis. Prentice-Hall, Hoboken.</mixed-citation></ref><ref id="scirp.123424-ref48"><label>48</label><mixed-citation publication-type="other" xlink:type="simple">Mardia, K.V., Kent, J.T. and Bibby, J.M. (1979) Multivariate Analysis. Academic Press, New York.</mixed-citation></ref><ref id="scirp.123424-ref49"><label>49</label><mixed-citation publication-type="other" xlink:type="simple">Pirouette 3.01 (2001) Infometrix, Inc., Woodinville.</mixed-citation></ref><ref id="scirp.123424-ref50"><label>50</label><mixed-citation publication-type="other" xlink:type="simple">Minitab, Inc. (2009) Minitab Statistical Software, Release 16 for Windows. State College.</mixed-citation></ref><ref id="scirp.123424-ref51"><label>51</label><mixed-citation publication-type="other" xlink:type="simple">Njogu, P.M., Gut, J., Rosenthal, P.J. and Chibale, K. (2013) Design, Synthesis, and Antiplasmodial Activity of Hybrid Compounds Based on (2R,3S)-N-Benzoyl-3-Phenylisoserine. ACS Medicinal Chemistry Letters, 4, 637-641.  
https://doi.org/10.1021/ml400164t</mixed-citation></ref><ref id="scirp.123424-ref52"><label>52</label><mixed-citation publication-type="other" xlink:type="simple">Politzer, P. and Murray, J. (2021) The Neglected Nuclei. Molecules, 26, 2982.  
https://doi.org/10.3390/molecules26102982</mixed-citation></ref><ref id="scirp.123424-ref53"><label>53</label><mixed-citation publication-type="other" xlink:type="simple">Thomsen, R. (2003) Flexible Ligand Docking Using Evolutionary Algorithms: Investigating the Effects of Variation Operators and Local Search Hybrids. Biosystems, 72, 57-73. https://doi.org/10.1016/S0303-2647(03)00135-7</mixed-citation></ref><ref id="scirp.123424-ref54"><label>54</label><mixed-citation publication-type="book" xlink:type="simple">Rawe, S.L. (2020) Artemisin and Artemisinin-Related Agents. In: Patrick, G.L, Ed., Antimalarial Agents: Design and Mechanism of Action, Elsevier, London, 99-132.  
https://doi.org/10.1016/B978-0-08-101210-9.00004-4</mixed-citation></ref><ref id="scirp.123424-ref55"><label>55</label><mixed-citation publication-type="other" xlink:type="simple">Chovsky′, J.V., Chu, K.C., Berendzen, J., Sweet, R.M. and Schlichting, I. (1999) Crystal Structures of Myoglobin-Ligand Complexes at Near-Atomic Resolution. Biophysical Journal, 77, 2153-2174. https://doi.org/10.1016/S0006-3495(99)77056-6</mixed-citation></ref><ref id="scirp.123424-ref56"><label>56</label><mixed-citation publication-type="other" xlink:type="simple">Protein Data Bank. The Rutgers State University. Piscataway, New Jersey.  
http://www.resb.org/pdb</mixed-citation></ref><ref id="scirp.123424-ref57"><label>57</label><mixed-citation publication-type="other" xlink:type="simple">ChemPlus: Modular Extensions to HyperChem Release 8.06. (2008) Molecular Modeling for Windows. Hyperchem, Inc., Gainesville.</mixed-citation></ref><ref id="scirp.123424-ref58"><label>58</label><mixed-citation publication-type="other" xlink:type="simple">Todeschini, R. and Consonni, V. (2009) Molecular Descriptors for Chemoinformatics. Wiley-VCH, New York. https://doi.org/10.1002/9783527628766</mixed-citation></ref><ref id="scirp.123424-ref59"><label>59</label><mixed-citation publication-type="other" xlink:type="simple">Bernardinelli, G., Jefford, C.W., Marie, D., Thomson, C. and Weber, J. (1994) Computational Studies of the Structures and Properties of Potential Antimalarial Compounds Based on the 1,2,4-Trioxane Ring Structure. I. Artemisinin-Like Molecules. International Journal of Quantum Chemistry: Quantum Biology Symposium, 21, 117-131. https://doi.org/10.1002/qua.560520710</mixed-citation></ref><ref id="scirp.123424-ref60"><label>60</label><mixed-citation publication-type="other" xlink:type="simple">Posner, G.H, Cumming, J.N., Ploypradith, P. and Oh, C.H. (1995) Evidence for Fe(IV) = O in the Molecular Mechanism of Action of the Trioxane Antimalarial Artemisinin. Journal of the American Chemical Society, 117, 5885-5886.  
https://doi.org/10.1021/ja00126a042</mixed-citation></ref><ref id="scirp.123424-ref61"><label>61</label><mixed-citation publication-type="other" xlink:type="simple">Jefford, C.W., Grigorov, M., weber, J., Lüthi, H.P. and Troncher, J.M.J. (2000) Correlating the Molecular Electrostatic Potentials of Some Organic Peroxides with Their Antimalarial Activities. Journal of Chemical Information and Computer Sciences, 40, 354-357. https://doi.org/10.1021/ci990276u</mixed-citation></ref><ref id="scirp.123424-ref62"><label>62</label><mixed-citation publication-type="other" xlink:type="simple">Cardoso, F.J.B., Figueiredo, A.F., Lobato, M.S., Miranda, R.M., Almeida, R.C.O. and Pinheiro, J.C. (2008) A Study on Antimalarial Artemisinin Derivatives Using MEP Maps and Multivariate QSAR. Journal of Molecular Modeling, 14, 39-48.  
https://doi.org/10.1007/s00894-007-0249-9</mixed-citation></ref><ref id="scirp.123424-ref63"><label>63</label><mixed-citation publication-type="other" xlink:type="simple">Meunier, B. and Robert, A. (2010) Heme as Trigger and Target for Trioxane-Containing Antimalarial Drugs. Accounts of Chemical Research, 43, 1444-1451.  
https://doi.org/10.1021/ar100070k</mixed-citation></ref><ref id="scirp.123424-ref64"><label>64</label><mixed-citation publication-type="other" xlink:type="simple">Cheng, F., Shen, J., Luo, X., Zhu, W., Gu, J., Ji, R., Jiang, H. and Chen, K. (2002) Molecular Docking and 3-D-QSAR Studies on the Possible Antimalarial Mechanism of Artemisinin Analogues. Bioorganic Medicinal &amp; Chemistry, 10, 2883-2891.  
https://doi.org/10.1016/S0968-0896(02)00161-X</mixed-citation></ref><ref id="scirp.123424-ref65"><label>65</label><mixed-citation publication-type="other" xlink:type="simple">Tonmunphean, S., Parasuk, V. and Kokpol, S. (2001) Automated Calculation of Docking of Artemisinin to Heme. Journal of Molecular Modeling, 7, 26-33.  
https://doi.org/10.1007/s008940100013</mixed-citation></ref><ref id="scirp.123424-ref66"><label>66</label><mixed-citation publication-type="other" xlink:type="simple">Ferreira, M.M.C. (2015) Químiometria: Conceitos, Métodos e Aplicacoes. UNICAMP, Campinas. https://doi.org/10.7476/9788526814714</mixed-citation></ref><ref id="scirp.123424-ref67"><label>67</label><mixed-citation publication-type="other" xlink:type="simple">Bulat, F.A., Murray, J.S. and Politzer, P. (2021) Identifying the Most Energetic Electrons in a Molecule: The Highest Occupied Molecular Orbital and the Average Local Ionization Energy. Computational and Theoretical Chemistry, 1199, Article ID: 113192. https://doi.org/10.1016/j.comptc.2021.113192</mixed-citation></ref><ref id="scirp.123424-ref68"><label>68</label><mixed-citation publication-type="other" xlink:type="simple">Todeschini, R. and Consonni, V. (2000) Handbook of Molecular Descriptors. Wiley, New York. https://doi.org/10.1002/9783527613106</mixed-citation></ref></ref-list></back></article>